Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 1019 articles:
HTML format



Single Articles


    July 2021
  1. LAANSMA MA, Bright JK, Al-Bachari S, Anderson TJ, et al
    International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
    Mov Disord. 2021 Jul 20. doi: 10.1002/mds.28706.
    PubMed     Abstract available


  2. SARASSO E, Agosta F, Piramide N, Gardoni A, et al
    Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study.
    Mov Disord. 2021 Jul 19. doi: 10.1002/mds.28717.
    PubMed     Abstract available


  3. GROS P, Wang X, Guan J, Lang AE, et al
    Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.
    Mov Disord. 2021 Jul 9. doi: 10.1002/mds.28712.
    PubMed     Abstract available


  4. CONCHA-MARAMBIO L, Farris CM, Holguin B, Ma Y, et al
    Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28715.
    PubMed    


  5. FREIRE-ALVAREZ E, Kurca E, Lopez Manzanares L, Pekkonen E, et al
    Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28703.
    PubMed     Abstract available


  6. MULLER-NEDEBOCK AC, Komolafe MA, Fawale MB, Carr JA, et al
    Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa.
    Mov Disord. 2021 Jul 6. doi: 10.1002/mds.28710.
    PubMed    


  7. SCHILLING M, Lill CM
    MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression.
    Mov Disord. 2021 Jul 5. doi: 10.1002/mds.28700.
    PubMed    


  8. CHOONG CJ, Kimura Y, Mochizuki H
    Disturbed Mitochondria-Lysosome Crosstalk in GBA1-Associated Parkinson's Disease.
    Mov Disord. 2021 Jul 1. doi: 10.1002/mds.28693.
    PubMed    


    June 2021
  9. VIDENOVIC A, Amara AW, Comella C, Schweitzer PK, et al
    Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Mov Disord. 2021 Jun 30. doi: 10.1002/mds.28702.
    PubMed     Abstract available


  10. PATEL SG, Buchanan CM, Mulroy E, Simpson M, et al
    Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.
    Mov Disord. 2021 Jun 22. doi: 10.1002/mds.28665.
    PubMed    


  11. FIORENZATO E, Antonini A, Bisiacchi P, Weis L, et al
    Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Jun 14. doi: 10.1002/mds.28682.
    PubMed     Abstract available


  12. NIGAM M, Ayadi I, Noiray C, Branquino-Bras AC, et al
    Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28692.
    PubMed     Abstract available


  13. GELPI E, Haberler C, Micko A, Polt A, et al
    Focal Subthalamic Atrophy After Long-Term Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28653.
    PubMed    


  14. MAITI B, Rawson KS, Tanenbaum AB, Koller JM, et al
    Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease.
    Mov Disord. 2021 Jun 10. doi: 10.1002/mds.28684.
    PubMed     Abstract available


  15. MUNOZ-DELGADO L, Macias-Garcia D, Jesus S, Martin-Rodriguez JF, et al
    Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease.
    Mov Disord. 2021 Jun 8. doi: 10.1002/mds.28685.
    PubMed     Abstract available


  16. SEGER AD, Farrher E, Doppler CEJ, Gogishvili A, et al
    Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
    Mov Disord. 2021 Jun 7. doi: 10.1002/mds.28674.
    PubMed     Abstract available


  17. HAMID E, Ayele BA, Massi DG, Ben Sassi S, et al
    Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
    Mov Disord. 2021 Jun 3. doi: 10.1002/mds.28669.
    PubMed     Abstract available


  18. ISONAKA R, Goldstein DS, Zhu W, Yoon E, et al
    alpha-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
    Mov Disord. 2021 Jun 2. doi: 10.1002/mds.28667.
    PubMed     Abstract available


  19. MATHUR S
    Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients.
    Mov Disord. 2021;36:1290-1292.
    PubMed    


    May 2021
  20. CARVALHO V, Ferreira JJ, Correia Guedes L
    Tremor and Parkinsonism in Chromosomopathies - A Systematic Review.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28663.
    PubMed     Abstract available


  21. CONEYS R, Storm CS, Kia DA, Almramhi M, et al
    Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28662.
    PubMed     Abstract available


  22. FEARON C, Mikulis DJ, Lang AE
    Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28656.
    PubMed    


  23. BOUALI-BENAZZOUZ R, Benazzouz A
    Covid-19 Infection and Parkinsonism: Is There a Link?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28680.
    PubMed     Abstract available


  24. ORSO B, Arnaldi D, Girtler N, Brugnolo A, et al
    Dopaminergic and Serotonergic Degeneration and Cortical [(18) F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28654.
    PubMed     Abstract available


  25. DEAN DN, Lee JC
    Linking Parkinson's Disease and Melanoma: Interplay Between alpha-Synuclein and Pmel17 Amyloid Formation.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28655.
    PubMed     Abstract available


  26. SCHWEDHELM E, Englisch C, Niemann L, Lezius S, et al
    Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD).
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28652.
    PubMed     Abstract available


  27. TOFFOLI M, Higgins A, Lee C, Koletsi S, et al
    Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28616.
    PubMed     Abstract available


  28. STUENDL A, Kraus T, Chatterjee M, Zapke B, et al
    alpha-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28639.
    PubMed     Abstract available


  29. O'SULLIVAN JM, den Heijer JM, Groeneveld GJ, Cooper AA, et al
    Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28620.
    PubMed    


  30. HAN F, Brown GL, Zhu Y, Belkin-Rosen AE, et al
    Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
    Mov Disord. 2021 May 17. doi: 10.1002/mds.28643.
    PubMed     Abstract available


  31. MORLEY D, Dummett S, Kelly L, Jenkinson C, et al
    Development of an Exercise-Specific Parkinson's Disease Questionnaire: The PDQ-Exercise.
    Mov Disord. 2021 May 15. doi: 10.1002/mds.28644.
    PubMed     Abstract available


  32. MARRAS C, Mills KA, Eberly S, Oakes D, et al
    Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients With Early Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28641.
    PubMed     Abstract available


  33. RICCIARDI L, Fischer P, Mostofi A, Tinkhauser G, et al
    Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28625.
    PubMed     Abstract available


  34. ESTIAR MA, Senkevich K, Yu E, Varghaei P, et al
    Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28640.
    PubMed     Abstract available


  35. COLLOBY SJ, Nathan PJ, Bakker G, Lawson RA, et al
    Spatial Covariance of Cholinergic Muscarinic M1 /M4 Receptors in Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28564.
    PubMed     Abstract available


  36. NAITO T, Satake W, Ogawa K, Suzuki K, et al
    Trans-Ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28583.
    PubMed     Abstract available


  37. BARBUTI PA, Barker RA, Brundin P, Przedborski S, et al
    Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
    Mov Disord. 2021 May 8. doi: 10.1002/mds.28628.
    PubMed     Abstract available


  38. IWAKI H, Leonard HL, Makarious MB, Bookman M, et al
    Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28549.
    PubMed     Abstract available


  39. DI LAZZARO G, Magrinelli F, Estevez-Fraga C, Valente EM, et al
    X-Linked Parkinsonism: Phenotypic and Genetic Heterogeneity.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28565.
    PubMed     Abstract available


  40. MCINTOSH E, Kent S, Gray A, Clarke CE, et al
    Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28623.
    PubMed     Abstract available


  41. MIRELMAN A, Ben Or Frank M, Melamed M, Granovsky L, et al
    Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28631.
    PubMed     Abstract available


  42. KAASINEN V, Vahlberg T, Stoessl AJ, Strafella AP, et al
    Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28632.
    PubMed     Abstract available


  43. KREMER T, Taylor KI, Siebourg-Polster J, Gerken T, et al
    Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28608.
    PubMed     Abstract available


  44. SCHERBAUM R, Kwon EH, Richter D, Bartig D, et al
    Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28586.
    PubMed     Abstract available


  45. MESTRE TA, Macklin EA, Ascherio A, Ferreira JJ, et al
    Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28630.
    PubMed     Abstract available


  46. SCOTT GD, Lim MM, Drake MG, Woltjer R, et al
    Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans.
    Mov Disord. 2021 May 3. doi: 10.1002/mds.28636.
    PubMed     Abstract available


  47. KIEBURTZ K, Olanow CW
    Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".
    Mov Disord. 2021;36:1281-1282.
    PubMed    


  48. SIMON DK
    A New Approach to the Development of Disease-Modifying Therapies for PD.
    Mov Disord. 2021;36:1281.
    PubMed    


  49. LERCHE S, Schulte C, Wurster I, Machetanz G, et al
    The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA.
    Mov Disord. 2021;36:1216-1228.
    PubMed     Abstract available


    April 2021
  50. YILMAZ R, Suenkel U, Postuma RB, Heinzel S, et al
    Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies.
    Mov Disord. 2021 Apr 30. doi: 10.1002/mds.28637.
    PubMed    


  51. SARANZA G, Villanueva EQ 3rd, Lang AE
    Preferences for Communication About End-of-Life Care in Atypical Parkinsonism.
    Mov Disord. 2021 Apr 28. doi: 10.1002/mds.28633.
    PubMed     Abstract available


  52. HUYNH B, Fu Y, Kirik D, Shine JM, et al
    Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
    Mov Disord. 2021 Apr 26. doi: 10.1002/mds.28615.
    PubMed     Abstract available


  53. TSUNEMI T, Oyama G, Saiki S, Hatano T, et al
    Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Mov Disord. 2021 Apr 25. doi: 10.1002/mds.28595.
    PubMed     Abstract available


  54. LETA V, Rodriguez-Violante M, Abundes A, Rukavina K, et al
    Parkinson's disease and Post-COVID-19 syndrome: The Parkinson's Long-COVID spectrum.
    Mov Disord. 2021 Apr 22. doi: 10.1002/mds.28622.
    PubMed    


  55. LI C, Ou R, Chen Y, Gu X, et al
    Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study.
    Mov Disord. 2021 Apr 21. doi: 10.1002/mds.28621.
    PubMed     Abstract available


  56. CHEN Y, Wu W, Zhao S, Lv X, et al
    Increased Accumulation of alpha-Synuclein in Inflamed Appendices of Parkinson's Disease Patients.
    Mov Disord. 2021 Apr 20. doi: 10.1002/mds.28553.
    PubMed     Abstract available


  57. JOHNSON LA, Aman JE, Yu Y, Escobar Sanabria D, et al
    High-Frequency Oscillations in the Pallidum: A Pathophysiological Biomarker in Parkinson's Disease?
    Mov Disord. 2021 Apr 13. doi: 10.1002/mds.28566.
    PubMed     Abstract available


  58. SOARES C, Carneiro DR, Dias R, Ferreira D, et al
    Behind the mask: recognizing facial features of Parkinson's disease during the COVID-19 pandemic.
    Mov Disord. 2021 Apr 9. doi: 10.1002/mds.28619.
    PubMed    


  59. ZAHED H, Zuzuarregui JRP, Gilron R, Denison T, et al
    The Neurophysiology of Sleep in Parkinson's Disease.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28562.
    PubMed     Abstract available


  60. LIM SH, Ferdousi M, Kalteniece A, Mahfoud ZR, et al
    Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28602.
    PubMed     Abstract available


  61. JIANG C, Hopfner F, Berg D, Hu MT, et al
    Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28591.
    PubMed     Abstract available


  62. KOOHI N, Bancroft MJ, Patel J, Castro P, et al
    Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations.
    Mov Disord. 2021 Apr 6. doi: 10.1002/mds.28609.
    PubMed    


  63. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28575.
    PubMed     Abstract available


  64. UEDA J, Uemura N, Sawamura M, Taguchi T, et al
    Perampanel Inhibits alpha-Synuclein Transmission in Parkinson's Disease Models.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28558.
    PubMed     Abstract available


  65. NIJHUIS FAP, Esselink R, de Bie RMA, Groenewoud H, et al
    Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
    Mov Disord. 2021 Apr 2. doi: 10.1002/mds.28599.
    PubMed     Abstract available


  66. HELMICH RC, Van den Berg KRE, Panyakaew P, Cho HJ, et al
    Cerebello-Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease.
    Mov Disord. 2021 Apr 1. doi: 10.1002/mds.28603.
    PubMed    


  67. GUTTLER C, Nikulin VV, van Riesen C
    Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
    Mov Disord. 2021;36:1045-1047.
    PubMed    


  68. SCHMIDT SL, Grill WM
    Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2021;36:1044-1045.
    PubMed    


  69. NEUMANN WJ, Rodriguez-Oroz MC
    Machine Learning Will Extend the Clinical Utility of Adaptive Deep Brain Stimulation.
    Mov Disord. 2021;36:796-799.
    PubMed    


  70. RUSZ J, Tykalova T, Ramig LO, Tripoliti E, et al
    Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders.
    Mov Disord. 2021;36:803-814.
    PubMed     Abstract available


  71. GEORGIEV D, Roskar S, Cus A, Wilkinson L, et al
    STN-DBS Increases Proactive but Not Retroactive Interference During Verbal Learning in PD.
    Mov Disord. 2021;36:1010-1015.
    PubMed     Abstract available


  72. OSHIMA S, Fushimi Y, Okada T, Nakajima S, et al
    Neuromelanin-Sensitive Magnetic Resonance Imaging Using DANTE Pulse.
    Mov Disord. 2021;36:874-882.
    PubMed     Abstract available


  73. BOOTH S, Ramadan A, Zhang D, Lu L, et al
    The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
    Mov Disord. 2021;36:938-947.
    PubMed     Abstract available


    March 2021
  74. VISANJI NP, Lang AE
    Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28590.
    PubMed    


  75. KLUGER BM, Dolhun R, Sumrall M, Hall K, et al
    Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28556.
    PubMed    


  76. SCHIESS M, Suescun J, Doursout MF, Adams C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
    Mov Disord. 2021 Mar 27. doi: 10.1002/mds.28582.
    PubMed     Abstract available


  77. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021 Mar 25. doi: 10.1002/mds.28594.
    PubMed     Abstract available


  78. GROVER S, Kumar-Sreelatha AA, Bobbili DR, May P, et al
    Replication of a Novel Parkinson's Locus in a European Ancestry Population.
    Mov Disord. 2021 Mar 24. doi: 10.1002/mds.28546.
    PubMed     Abstract available


  79. ABRAHAM DS, Pham Nguyen TP, Willis AW
    Claims-Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease.
    Mov Disord. 2021 Mar 23. doi: 10.1002/mds.28561.
    PubMed     Abstract available


  80. YAO CW, Saha-Chaudhuri P, Zolfaghari S, Pelletier A, et al
    Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population-Based CLSA.
    Mov Disord. 2021 Mar 22. doi: 10.1002/mds.28571.
    PubMed    


  81. SALARI M, Etemadifar M, Zali A, Medghalchi A, et al
    Seroprevalence of SARS-CoV-2 in Parkinson's Disease Patients: A Case-Control Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28580.
    PubMed    


  82. MARINI K, Seppi K, Tschiderer L, Kiechl S, et al
    Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28570.
    PubMed    


  83. CANONICO M, Pesce G, Bonaventure A, Le Noan-Laine M, et al
    Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy.
    Mov Disord. 2021 Mar 16. doi: 10.1002/mds.28563.
    PubMed     Abstract available


  84. DOBKIN RD, Mann SL, Weintraub D, Rodriguez KM, et al
    Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment.
    Mov Disord. 2021 Mar 12. doi: 10.1002/mds.28548.
    PubMed     Abstract available


  85. GAURAV R, Yahia-Cherif L, Pyatigorskaya N, Mangone G, et al
    Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Mov Disord. 2021 Mar 10. doi: 10.1002/mds.28531.
    PubMed     Abstract available


  86. CHOHAN H, Senkevich K, Patel RK, Bestwick JP, et al
    Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
    Mov Disord. 2021 Mar 8. doi: 10.1002/mds.28551.
    PubMed     Abstract available


  87. DUYSENS J, Nonnekes J
    Parkinson's Kinesia Paradoxa Is Not a Paradox.
    Mov Disord. 2021 Mar 3. doi: 10.1002/mds.28550.
    PubMed    


  88. CLAUS I, Muhle P, Czechowski J, Ahring S, et al
    Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease.
    Mov Disord. 2021 Mar 2. doi: 10.1002/mds.28552.
    PubMed     Abstract available


  89. FEARON C, Lang AE, Espay AJ
    The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes.
    Mov Disord. 2021;36:594-598.
    PubMed    


  90. BORGHAMMER P, Horsager J
    The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes.
    Mov Disord. 2021;36:785-786.
    PubMed    


  91. FEARON C, Lang AE, J Espay A
    Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes".
    Mov Disord. 2021;36:786-787.
    PubMed    


  92. SARTER M, Avila C, Kucinski A, Donovan E, et al
    Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.
    Mov Disord. 2021;36:535-546.
    PubMed     Abstract available


  93. YOUNCE JR, Campbell MC, Hershey T, Tanenbaum AB, et al
    Resting-State Functional Connectivity Predicts STN DBS Clinical Response.
    Mov Disord. 2021;36:662-671.
    PubMed     Abstract available


  94. POLISSIDIS A, Koronaiou M, Kollia V, Koronaiou E, et al
    Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human alpha-Synuclein BAC Transgenic Rats.
    Mov Disord. 2021;36:716-728.
    PubMed     Abstract available


  95. HANSS Z, Larsen SB, Antony P, Mencke P, et al
    Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
    Mov Disord. 2021;36:704-715.
    PubMed     Abstract available


    February 2021
  96. DE MICCO R, Agosta F, Basaia S, Siciliano M, et al
    Functional Connectomics and Disease Progression in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28541.
    PubMed     Abstract available


  97. BURTSCHER J, Syed MMK, Lashuel HA, Millet GP, et al
    Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28544.
    PubMed     Abstract available


  98. MARKAKI I, Ntetsika T, Sorjonen K, Svenningsson P, et al
    Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28545.
    PubMed     Abstract available


  99. CHAHINE LM, Zhu X, Ehrenkranz R, Chen H, et al
    Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28535.
    PubMed    


  100. KAKAR RS, Pastor JV, Moe OW, Ambrosio F, et al
    Peripheral Klotho and Parkinson's Disease.
    Mov Disord. 2021 Feb 25. doi: 10.1002/mds.28530.
    PubMed    


  101. MOONEN AJH, Mulders AEP, Defebvre L, Duits A, et al
    Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28533.
    PubMed     Abstract available


  102. AVENALI M, Cerri S, Ongari G, Ghezzi C, et al
    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28496.
    PubMed     Abstract available


  103. LIU H, Koros C, Strohaker T, Schulte C, et al
    A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28534.
    PubMed     Abstract available


  104. SONG S, Luo Z, Li C, Huang X, et al
    Changes in Body Composition Before and After Parkinson's Disease Diagnosis.
    Mov Disord. 2021 Feb 22:e28536. doi: 10.1002/mds.28536.
    PubMed     Abstract available


  105. AEED F, Cermak N, Schiller J, Schiller Y, et al
    Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2021 Feb 19. doi: 10.1002/mds.28538.
    PubMed     Abstract available


  106. KLEINER G, Fernandez HH, Chou KL, Fasano A, et al
    Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire.
    Mov Disord. 2021 Feb 15. doi: 10.1002/mds.28507.
    PubMed     Abstract available


  107. GALPER J, Balwani M, Fahn S, Waters C, et al
    Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers With and Without Parkinson Disease.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28525.
    PubMed     Abstract available


  108. BRIGHT JM, Carlisle HJ, Toda AMA, Murphy M, et al
    Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28490.
    PubMed     Abstract available


  109. PAZ RM, Tubert C, Stahl AM, Amarillo Y, et al
    Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
    Mov Disord. 2021 Feb 6. doi: 10.1002/mds.28516.
    PubMed     Abstract available


  110. ANTAR T, Iwaki H, B Singleton A
    Reply to: 'Letter to the Editor on "Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities"'.
    Mov Disord. 2021;36:527-528.
    PubMed    


  111. OUTEIRO TF, Krisko A
    Reply to: "Parkinson's Disease and COVID-19: Do We Need to Be More Patient?"
    Mov Disord. 2021;36:278-279.
    PubMed    


  112. GONZALEZ-LATAPI P, Fearon C, Fasano A, Lang AE, et al
    Parkinson's Disease and COVID-19: Do We Need to Be More Patient?
    Mov Disord. 2021;36:277.
    PubMed    


  113. DE LA ROSA T, Amado Scerni D, Scorza FA
    Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities.
    Mov Disord. 2021;36:526.
    PubMed    


  114. HO GPH, Ramalingam N, Imberdis T, Wilkie EC, et al
    Upregulation of Cellular Palmitoylation Mitigates alpha-Synuclein Accumulation and Neurotoxicity.
    Mov Disord. 2021;36:348-359.
    PubMed     Abstract available


    January 2021
  115. MULLER-NEDEBOCK AC, van der Westhuizen FH, Koks S, Bardien S, et al
    Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28475.
    PubMed     Abstract available


  116. JEONG SH, Lee HS, Jung JH, Baik K, et al
    White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28510.
    PubMed     Abstract available



  117. GP2: The Global Parkinson's Genetics Program.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28494.
    PubMed    


  118. KIM JJ, Makarious MB, Bandres-Ciga S, Gibbs JR, et al
    The Parkinson's Disease DNA Variant Browser.
    Mov Disord. 2021 Jan 26. doi: 10.1002/mds.28488.
    PubMed     Abstract available


  119. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28462.
    PubMed     Abstract available


  120. DONAHUE EK, Murdos A, Jakowec MW, Sheikh-Bahaei N, et al
    Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28473.
    PubMed     Abstract available


  121. WELTON T, Tan EK
    Applying Artificial Intelligence to Multi-Omic Data: New Functional Variants in Parkinson's Disease.
    Mov Disord. 2021 Jan 17. doi: 10.1002/mds.28481.
    PubMed    


  122. MICHELI F, Vissani M, Pecchioli G, Terenzi F, et al
    Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity.
    Mov Disord. 2021 Jan 16. doi: 10.1002/mds.28497.
    PubMed     Abstract available


  123. AVRAM CM, Brumbach BH, Hiller AL
    A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28471.
    PubMed     Abstract available


  124. LIN CH, Chang CH, Tai CH, Cheng MF, et al
    A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28474.
    PubMed     Abstract available


  125. RAVANIDIS S, Bougea A, Karampatsi D, Papagiannakis N, et al
    Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 12. doi: 10.1002/mds.28467.
    PubMed     Abstract available


  126. HERZ DM, Meder D, Camilleri JA, Eickhoff SB, et al
    Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28468.
    PubMed     Abstract available


  127. VILA-VICOSA D, Clemente A, Pona-Ferreira F, Leitao M, et al
    Unsupervised walking activity assessment reveals COVID-19 impact on Parkinson's disease patients.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28514.
    PubMed    


  128. ZARKALI A, McColgan P, Leyland LA, Lees AJ, et al
    Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
    Mov Disord. 2021 Jan 9. doi: 10.1002/mds.28477.
    PubMed     Abstract available


  129. KUUSIMAKI T, Al-Abdulrasul H, Kurki S, Hietala J, et al
    Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28484.
    PubMed     Abstract available


  130. CHEN L, Bedard P, Hallett M, Horovitz SG, et al
    Dynamics of Top-Down Control and Motor Networks in Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28461.
    PubMed     Abstract available


  131. SCHIRINZI T, Maftei D, Pieri M, Bernardini S, et al
    Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28458.
    PubMed    


  132. METCALFE-ROACH A, Yu AC, Golz E, Cirstea M, et al
    MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28464.
    PubMed     Abstract available


  133. BAUMGARTNER AJ, Press DZ, Simon DK
    The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28483.
    PubMed    


  134. CHOE CU, Potter-Nerger M, Buhmann C, Blankenberg S, et al
    Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease".
    Mov Disord. 2021;36:273-274.
    PubMed    


  135. TRILCK-WINKLER M, Borsche M, Konig IR, Balck A, et al
    Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
    Mov Disord. 2021;36:271-273.
    PubMed    


  136. WITT K
    The Impact of the Basal Ganglia on Working Memory: Evidence from Parkinson's Disease.
    Mov Disord. 2021;36:13-15.
    PubMed    


  137. FULLER RLM, Sanchez-Ferro A, Goetz CG, Martinez-Martin P, et al
    In Support of Electronic Versions of Movement Disorder Society Rating Scales.
    Mov Disord. 2021;36:270-271.
    PubMed    


  138. TURNER TH, Dale ML
    Reply to: "In Support of Electronic Versions of Movement Disorder Society Rating Scales".
    Mov Disord. 2021;36:271.
    PubMed    


  139. SARANZA G, Lang AE
    Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
    Mov Disord. 2021;36:265-266.
    PubMed    


  140. KIEBURTZ K, Katz R, McGarry A, Olanow CW, et al
    A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
    Mov Disord. 2021;36:59-63.
    PubMed     Abstract available


  141. VIEIRA-YANO B, Martini DN, Horak FB, de Lima-Pardini A, et al
    The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity.
    Mov Disord. 2021;36:152-163.
    PubMed     Abstract available


    December 2020
  142. WILSON J, Yarnall AJ, Craig CE, Galna B, et al
    Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Mov Disord. 2020 Dec 31. doi: 10.1002/mds.28453.
    PubMed     Abstract available


  143. DUITS AA, Boots LMM, Mulders AEP, Moonen AJH, et al
    Covid Proof Self-Management Training for Caregivers of Patients with Parkinson's Disease.
    Mov Disord. 2020 Dec 27. doi: 10.1002/mds.28457.
    PubMed    


  144. FILIPPOU P, Outeiro TF
    Cancer and Parkinson's Disease: Common Targets, Emerging Hopes.
    Mov Disord. 2020 Dec 21. doi: 10.1002/mds.28425.
    PubMed     Abstract available


  145. NISSEN SK, Ferreira SA, Nielsen MC, Schulte C, et al
    Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
    Mov Disord. 2020 Dec 17. doi: 10.1002/mds.28424.
    PubMed     Abstract available


  146. ZOON TJC, van Rooijen G, Balm GMFC, Bergfeld IO, et al
    Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2020 Dec 16. doi: 10.1002/mds.28390.
    PubMed     Abstract available


  147. SKRAHINA V, Gaber H, Vollstedt EJ, Forster TM, et al
    The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28416.
    PubMed     Abstract available


  148. KLINE EM, Houser MC, Herrick MK, Seibler P, et al
    Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28411.
    PubMed     Abstract available


  149. ELFIL M, Bahbah EI, Attia MM, Eldokmak M, et al
    Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease.
    Mov Disord. 2020 Dec 9. doi: 10.1002/mds.28412.
    PubMed     Abstract available


  150. MULLIN S, Stokholm MG, Hughes D, Mehta A, et al
    Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.
    Mov Disord. 2020 Dec 5. doi: 10.1002/mds.28375.
    PubMed     Abstract available


  151. CAREY G, Gormezoglu M, de Jong JJA, Hofman PAM, et al
    Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2020 Dec 2. doi: 10.1002/mds.28404.
    PubMed     Abstract available


  152. OLSZEWSKA DA, Lang AE
    "Opening" New Insights Into LRRK2 Conformation and the Microtubule.
    Mov Disord. 2020;35:2162-2163.
    PubMed    


    November 2020
  153. MARTIN WRW, Miles M, Zhong Q, Hartlein J, et al
    Is Levodopa Response a Valid Indicator of Parkinson's Disease?
    Mov Disord. 2020 Nov 30. doi: 10.1002/mds.28406.
    PubMed     Abstract available


  154. GUTTLER C, Altschuler J, Tanev K, Bockmann S, et al
    Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2020 Nov 28. doi: 10.1002/mds.28403.
    PubMed     Abstract available


  155. PORTLEY MK, Scholz SW
    Hot Topic: Epigenetics in Parkinson's Disease: A New Frontier for Disease-Modifying Therapies.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28410.
    PubMed    


  156. SANTOS-GARCIA D, Pozojevic J, de Deus Fonticoba T, Kurtis M, et al
    First Case of Parkinsonian-Pyramidal Syndrome Associated with a TBK1 Mutation.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28405.
    PubMed    


  157. WALDTHALER J, Stock L, Sommerkorn J, Kruger-Zechlin C, et al
    Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease.
    Mov Disord. 2020 Nov 25. doi: 10.1002/mds.28374.
    PubMed    


  158. AL-QASSABI A, Tsao TS, Racolta A, Kremer T, et al
    Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28399.
    PubMed     Abstract available


  159. JAAKKOLA E, Huovinen A, Kaasinen V, Joutsa J, et al
    No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28400.
    PubMed    


  160. GARCIA-SANZ P, M F G Aerts J, Moratalla R
    The Role of Cholesterol in alpha-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease.
    Mov Disord. 2020 Nov 21. doi: 10.1002/mds.28396.
    PubMed     Abstract available


  161. PAGAN FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, et al
    Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
    Mov Disord. 2020 Nov 20. doi: 10.1002/mds.28389.
    PubMed     Abstract available


  162. ERREA O, Rodriguez-Oroz MC
    Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease.
    Mov Disord. 2020 Nov 18. doi: 10.1002/mds.28393.
    PubMed    


  163. OJUKWU DI, Andruska KM, Halpern CH
    Lessons From George Floyd: Racial Inequalities in the Treatment of Parkinson's Disease.
    Mov Disord. 2020 Nov 17. doi: 10.1002/mds.28388.
    PubMed    


  164. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28378.
    PubMed    


  165. OUTEIRO TF, Heutink P, Bezard E, Cenci AM, et al
    From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28387.
    PubMed     Abstract available


  166. VIGNATELLI L, Zenesini C, Belotti LMB, Baldin E, et al
    Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28408.
    PubMed     Abstract available


  167. MAETZLER W, Rochester L, Bhidayasiri R, Espay AJ, et al
    Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures.
    Mov Disord. 2020 Nov 15. doi: 10.1002/mds.28377.
    PubMed     Abstract available


  168. DEVOS D, Hirsch E, Wyse R
    Seven Solutions for Neuroprotection in Parkinson's Disease.
    Mov Disord. 2020 Nov 13. doi: 10.1002/mds.28379.
    PubMed     Abstract available


  169. DE MICCO R, Satolli S, Siciliano M, Di Nardo F, et al
    Connectivity Correlates of Anxiety Symptoms in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 10. doi: 10.1002/mds.28372.
    PubMed     Abstract available


  170. PICILLO M, Phokaewvarangkul O, Poon YY, McIntyre CC, et al
    Levodopa Versus Dopamine Agonist After Subthalamic Stimulation in Parkinson's Disease.
    Mov Disord. 2020 Nov 9. doi: 10.1002/mds.28382.
    PubMed     Abstract available


  171. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28364.
    PubMed     Abstract available


  172. SARIHAN EI, Perez-Palma E, Niestroj LM, Loesch D, et al
    Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28353.
    PubMed     Abstract available


  173. VAN DER ZEE S, Muller MLTM, Kanel P, van Laar T, et al
    Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28360.
    PubMed     Abstract available


  174. CHOUGAR L, Faouzi J, Pyatigorskaya N, Yahia-Cherif L, et al
    Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28348.
    PubMed     Abstract available


  175. DORSEY ER, Bloem BR, Okun MS
    A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.
    Mov Disord. 2020;35:1897-1902.
    PubMed     Abstract available


  176. HERRINGTON TM, Schweitzer J, Henchcliffe C, Carter BS, et al
    Toward a Personalized Approach to Parkinson's Cell Therapy.
    Mov Disord. 2020;35:2119-2120.
    PubMed    


  177. SILVA-BATISTA C, M Corcos D, B Horak F, Ugrinowitsch C, et al
    Reply to: 'Letter to the Editor on "A Randomized Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait"'.
    Mov Disord. 2020;35:2123-2124.
    PubMed    


  178. KORDOWER JH, Okun MS, Jankovic J
    Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy".
    Mov Disord. 2020;35:2120-2121.
    PubMed    


  179. NONNEKES J, Gilat M, D'Cruz N, Dijkstra BW, et al
    Letter to the Editor on "A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait".
    Mov Disord. 2020;35:2122-2123.
    PubMed    


    October 2020
  180. TAN MMX, Lawton MA, Jabbari E, Reynolds RH, et al
    Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2020 Oct 28. doi: 10.1002/mds.28342.
    PubMed     Abstract available


  181. SUN YM, Yu HL, Zhou XY, Xiong WX, et al
    Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28349.
    PubMed     Abstract available


  182. MENOZZI E, Macnaughtan J, Schapira AHV
    LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28347.
    PubMed    


  183. VAN DEN HEUVEL L, Evers L, Meinders M, Post B, et al
    Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28339.
    PubMed     Abstract available


  184. BEYLERGIL SB, Petersen M, Gupta P, Elkasaby M, et al
    Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading.
    Mov Disord. 2020 Oct 26. doi: 10.1002/mds.28352.
    PubMed     Abstract available


  185. YE Z, Zhang G, Zhang Y, Li S, et al
    The Role of the Subthalamic Nucleus in Sequential Working Memory in De Novo Parkinson's Disease.
    Mov Disord. 2020 Oct 24. doi: 10.1002/mds.28344.
    PubMed     Abstract available


  186. VAN DER HEIDE A, Meinders MJ, Speckens AEM, Peerbolte TF, et al
    Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms.
    Mov Disord. 2020 Oct 23. doi: 10.1002/mds.28345.
    PubMed     Abstract available


  187. FU JF, Matarazzo M, McKenzie J, Neilson N, et al
    Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
    Mov Disord. 2020 Oct 22. doi: 10.1002/mds.28340.
    PubMed     Abstract available


  188. YIN W, Lof M, Pedersen NL, Sandin S, et al
    Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study.
    Mov Disord. 2020 Oct 20. doi: 10.1002/mds.28314.
    PubMed     Abstract available


  189. TAKEDA A, Takahashi R, Tsuboi Y, Nomoto M, et al
    Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations.
    Mov Disord. 2020 Oct 19. doi: 10.1002/mds.28322.
    PubMed     Abstract available


  190. LOWES H, Robertson F, Pyle A, Hussain R, et al
    The human coronavirus receptor ANPEP (CD13) is overexpressed in Parkinson's disease.
    Mov Disord. 2020 Oct 18. doi: 10.1002/mds.28354.
    PubMed    


  191. SCHLOSSMACHER MG, Graybiel AM
    Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28316.
    PubMed     Abstract available


  192. TAKAMIYA A, Seki M, Kudo S, Yoshizaki T, et al
    Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28335.
    PubMed     Abstract available


  193. MESTRE TA, Kessler D, Cote D, Liddy C, et al
    Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28332.
    PubMed     Abstract available


  194. BELVISI D, Fabbrini A, De Bartolo MI, Costanzo M, et al
    The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes.
    Mov Disord. 2020 Oct 10. doi: 10.1002/mds.28321.
    PubMed     Abstract available


  195. DAHODWALA N, Li P, Jahnke J, Ladage VP, et al
    Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
    Mov Disord. 2020 Oct 8. doi: 10.1002/mds.28265.
    PubMed     Abstract available


  196. SANTIN MDN, Voulleminot P, Vrillon A, Hainque E, et al
    Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2020 Oct 6. doi: 10.1002/mds.28320.
    PubMed     Abstract available


  197. ISRAEL Z, Asch N
    Reversing a Model of Parkinson's Disease With In Situ Converted Nigral Neurons.
    Mov Disord. 2020 Oct 5. doi: 10.1002/mds.28306.
    PubMed    


  198. BONVEGNA S, Straccia G, Golfre Andreasi N, Elia AE, et al
    Parkinsonism and Nigrostriatal Damage Secondary to CSF1R-Related Primary Microgliopathy.
    Mov Disord. 2020 Oct 3. doi: 10.1002/mds.28290.
    PubMed    


  199. KANE PB, Benjamin DM, Barker RA, Lang AE, et al
    Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28319.
    PubMed     Abstract available


  200. TSUBOI T, Charbel M, Peterside DT, Rana M, et al
    Pallidal Connectivity Profiling of Stimulation-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28324.
    PubMed     Abstract available


  201. IWAKI H, Blauwendraat C, Leonard HL, Makarious MB, et al
    Differences in the Presentation and Progression of Parkinson's Disease by Sex.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28312.
    PubMed     Abstract available


  202. MUFTI K, Rudakou U, Yu E, Krohn L, et al
    Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28318.
    PubMed     Abstract available


  203. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Reply to: "Can the 2019 Novel Coronavirus Cause Parkinson's Disease?"
    Mov Disord. 2020;35:1726.
    PubMed    


  204. HURWITZ B, Lees AJ, Walusinski O
    Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease.
    Mov Disord. 2020;35:1880-1881.
    PubMed    


  205. SULLIVAN R, Yau WY, Chelban V, Rossi S, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1890-1891.
    PubMed    


  206. DA SILVA SCHMITT G, Martinez ARM, da Graca FF, de Lima FD, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1889-1890.
    PubMed    


  207. AGUIRRE-PADILLA DH, Lozano AM, Fasano A
    Reply to: "Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?"
    Mov Disord. 2020;35:1883.
    PubMed    


  208. MONTGOMERY EB JR
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020;35:1891.
    PubMed    


  209. CURY RG, Carra RB, Capato TTC, Teixeira MJ, et al
    Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?
    Mov Disord. 2020;35:1882-1883.
    PubMed    


  210. MONJE MHG, Martinez-Fernandez R
    Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?
    Mov Disord. 2020;35:1725.
    PubMed    


  211. ALVES M, Caldeira D, Reimao S, Ferro JM, et al
    N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease.
    Mov Disord. 2020;35:1886-1887.
    PubMed    


  212. CHOE CU, Petersen E, Potter-Nerger M, Buhmann C, et al
    Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease".
    Mov Disord. 2020;35:1888.
    PubMed    


  213. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease".
    Mov Disord. 2020;35:1882.
    PubMed    


  214. CROTTY GF, Lo RY, Schwarzschild MA
    If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?
    Mov Disord. 2020;35:1727-1730.
    PubMed    


    September 2020
  215. BLUMENREICH S, Jenkins BJ, Barav OB, Milenkovic I, et al
    The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28232.
    PubMed    


  216. RAJPUT AH, Kish SJ
    Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28317.
    PubMed    


  217. AL ALI J, Vaine CA, Shah S, Campion L, et al
    TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 25. doi: 10.1002/mds.28305.
    PubMed     Abstract available


  218. YU E, Rudakou U, Krohn L, Mufti K, et al
    Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease.
    Mov Disord. 2020 Sep 24. doi: 10.1002/mds.28299.
    PubMed     Abstract available


  219. DOMMERSHUIJSEN LJ, Heshmatollah A, Mattace Raso FUS, Koudstaal PJ, et al
    Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
    Mov Disord. 2020 Sep 23. doi: 10.1002/mds.28303.
    PubMed     Abstract available


  220. MANNE S, Kondru N, Jin H, Serrano GE, et al
    Blinded RT-QuIC Analysis of alpha-Synuclein Biomarker in Skin Tissue from Parkinson's Disease Patients.
    Mov Disord. 2020 Sep 22. doi: 10.1002/mds.28242.
    PubMed     Abstract available


  221. DIAW SH, Lohmann K
    Linking Huntington's Disease and X-Linked Dystonia Parkinsonism on the Molecular Level.
    Mov Disord. 2020 Sep 22. doi: 10.1002/mds.28287.
    PubMed    


  222. TERROBA-CHAMBI C, Abulafia C, Vigo DE, Merello M, et al
    Heart Rate Variability and Mild Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Sep 21. doi: 10.1002/mds.28234.
    PubMed    


  223. ZHANG Q, Schultz JL, Aldridge GM, Simmering JE, et al
    COVID-19 case fatality and Parkinson's disease.
    Mov Disord. 2020 Sep 21. doi: 10.1002/mds.28325.
    PubMed    


  224. PAULY MG, Ruiz Lopez M, Westenberger A, Saranza G, et al
    Expanding Data Collection for the MDSGene Database: X-Linked Dystonia-Parkinsonism as Use Case Example.
    Mov Disord. 2020 Sep 19. doi: 10.1002/mds.28289.
    PubMed     Abstract available


  225. FLORIN E, Koschmieder KC, Schnitzler A, Becker S, et al
    Recovery of Impaired Endogenous Pain Modulation by Dopaminergic Medication in Parkinson's Disease.
    Mov Disord. 2020 Sep 18. doi: 10.1002/mds.28241.
    PubMed     Abstract available


  226. KRISMER F, Beliveau V, Seppi K, Mueller C, et al
    Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease.
    Mov Disord. 2020 Sep 16. doi: 10.1002/mds.28281.
    PubMed     Abstract available


  227. JUNG JH, Kim BH, Chung SJ, Yoo HS, et al
    Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease.
    Mov Disord. 2020 Sep 14. doi: 10.1002/mds.28243.
    PubMed     Abstract available


  228. TANTAWY AAG, Adly AAM, Hashem NH, Ebeid WM, et al
    Ganglion Cell Complex Thinning in Young Gaucher Patients: Relation to Prodromal Parkinsonian Markers.
    Mov Disord. 2020 Sep 12. doi: 10.1002/mds.28256.
    PubMed     Abstract available


  229. PERINAN MT, Macias-Garcia D, Labrador-Espinosa MA, Jesus S, et al
    Association of PICALM with Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Sep 11. doi: 10.1002/mds.28283.
    PubMed     Abstract available


  230. REIMAO S, Guerreiro C, Seppi K, Ferreira JJ, et al
    A Standardized MR Imaging Protocol for Parkinsonism.
    Mov Disord. 2020 Sep 11. doi: 10.1002/mds.28204.
    PubMed    


  231. KOGAN RV, Janzen A, Meles SK, Sittig E, et al
    Four-Year Follow-up of [(18) F]Fluorodeoxyglucose Positron Emission Tomography-Based Parkinson's Disease-Related Pattern Expression in 20 Patients With Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression.
    Mov Disord. 2020 Sep 10. doi: 10.1002/mds.28260.
    PubMed     Abstract available


  232. KRAUSE C, Schaake S, Grutz K, Sievert H, et al
    DNA Methylation as a Potential Molecular Mechanism in X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 10. doi: 10.1002/mds.28239.
    PubMed     Abstract available


  233. LI C, Ou R, Chen Y, Gu X, et al
    ATP10B and the Risk for Early-Onset Parkinson's Disease.
    Mov Disord. 2020 Sep 9. doi: 10.1002/mds.28285.
    PubMed    


  234. MELLO LGM, Bissoli LB, Saraiva FP, Maia RPD, et al
    Retinal Layers and Choroid Measurements in Parkinson's Disease with or Without Pramipexole Treatment.
    Mov Disord. 2020 Sep 9. doi: 10.1002/mds.28280.
    PubMed    


  235. TAN AH, Lim SY, Mahadeva S, Loke MF, et al
    Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial.
    Mov Disord. 2020 Sep 7. doi: 10.1002/mds.28248.
    PubMed     Abstract available


  236. FILIPPI M, Canu E, Donzuso G, Stojkovic T, et al
    Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2020 Sep 4. doi: 10.1002/mds.28228.
    PubMed     Abstract available


  237. SIPILA JOT, Kaasinen V
    No Change in the Age-Adjusted Incidence of Parkinson's Disease in Finland for More Than 25 Years.
    Mov Disord. 2020 Sep 2. doi: 10.1002/mds.28250.
    PubMed    


  238. CHEN SJ, Kuo CH, Kuo HC, Chen CC, et al
    The Gut Metabolite Trimethylamine N-Oxide Is Associated With Parkinson's Disease Severity and Progression.
    Mov Disord. 2020 Sep 2. doi: 10.1002/mds.28246.
    PubMed    


  239. ZHANG X
    Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease".
    Mov Disord. 2020;35:1695.
    PubMed    


  240. LU C, Amundsen Huffmaster SL, Louie KH, Sovell-Brown K, et al
    Pallidal Oscillation Dynamics Following Cessation of Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2020;35:1697-1698.
    PubMed    


  241. SPEECKAERT MM, Speeckaert R, Delanghe JR
    Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1497.
    PubMed    


  242. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Reply to: 'Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease"'.
    Mov Disord. 2020;35:1695-1697.
    PubMed    


  243. NEUMANN WJ, Feldmann L, Kuhn AA
    Reply to: Pallidal Low-Frequency Activity in Dystonia and Subthalamic Beta Activity in Parkinson's Disease.
    Mov Disord. 2020;35:1699.
    PubMed    


  244. CEREDA E, Fasano A, Pezzoli G
    Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1498.
    PubMed    


  245. WEIL RS
    Visual Dysfunction and Parkinson's Disease.
    Mov Disord. 2020;35:1499-1501.
    PubMed    


    August 2020
  246. SGAMBATO V
    Blood Flow as a Route for Bidirectional Propagation of Synucleinopathy in Parkinson's Disease?
    Mov Disord. 2020 Aug 31. doi: 10.1002/mds.28236.
    PubMed    


  247. GRENN FP, Kim JJ, Makarious MB, Iwaki H, et al
    The Parkinson's Disease Genome-Wide Association Study Locus Browser.
    Mov Disord. 2020 Aug 31. doi: 10.1002/mds.28197.
    PubMed     Abstract available


  248. CHEONG JLY, Goh ZHK, Marras C, Tanner CM, et al
    The impact of COVID-19 on access to Parkinson's disease medication.
    Mov Disord. 2020 Aug 28. doi: 10.1002/mds.28293.
    PubMed     Abstract available


  249. GREUEL A, Trezzi JP, Glaab E, Ruppert MC, et al
    GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes.
    Mov Disord. 2020 Aug 27. doi: 10.1002/mds.28225.
    PubMed     Abstract available


  250. STUART S, Morris R, Giritharan A, Quinn J, et al
    Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy.
    Mov Disord. 2020 Aug 24. doi: 10.1002/mds.28214.
    PubMed     Abstract available


  251. FOLLMER C
    Gut Microbiome Imbalance and Neuroinflammation: Impact of COVID-19 on Parkinson's Disease.
    Mov Disord. 2020 Aug 21. doi: 10.1002/mds.28231.
    PubMed    


  252. OLANOW CW, Calabresi P, Obeso JA
    Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities.
    Mov Disord. 2020 Aug 20. doi: 10.1002/mds.28215.
    PubMed     Abstract available


  253. FABER I, Brandao PRP, Menegatti F, Bispo DDC, et al
    Covid-19 and Parkinsonism: A non-post-encephalitic case.
    Mov Disord. 2020 Aug 19. doi: 10.1002/mds.28277.
    PubMed    


  254. MOLLENHAUER B, Dakna M, Kruse N, Galasko D, et al
    Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28206.
    PubMed     Abstract available


  255. MARKAKI I, Bergstrom S, Tsitsi P, Remnestal J, et al
    Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28192.
    PubMed     Abstract available


  256. PALERMO G, Tommasini L, Baldacci F, Del Prete E, et al
    Impact of COVID-19 pandemic on cognition in Parkinson's disease.
    Mov Disord. 2020 Aug 10. doi: 10.1002/mds.28254.
    PubMed    


  257. SANTOS GARCIA D, Oreiro M, Perez P, Fanjul G, et al
    Impact of COVID-19 Pandemic on Parkinson s Disease: A Cross-sectional Survey of 568 Spanish Patients.
    Mov Disord. 2020 Aug 10. doi: 10.1002/mds.28261.
    PubMed     Abstract available


  258. DELVA A, Van Weehaeghe D, Koole M, Van Laere K, et al
    Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease.
    Mov Disord. 2020 Aug 7. doi: 10.1002/mds.28216.
    PubMed     Abstract available


  259. BALESTRINO R, Tunesi S, Tesei S, Lopiano L, et al
    Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: a Kin Cohort Study.
    Mov Disord. 2020 Aug 7. doi: 10.1002/mds.28200.
    PubMed     Abstract available


  260. CHOI JH, Lee JY, Cho JW, Koh SB, et al
    Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study.
    Mov Disord. 2020 Aug 6. doi: 10.1002/mds.28219.
    PubMed     Abstract available


  261. DELLI PIZZI S, Franciotti R, Ferretti A, Edden RAE, et al
    High gamma-Aminobutyric Acid Content within the Medial Prefrontal Cortex Is a Functional Signature of Somatic Symptoms Disorder in Patients with Parkinson's Disease.
    Mov Disord. 2020 Aug 3. doi: 10.1002/mds.28221.
    PubMed     Abstract available


  262. ANTONINI A, Leta V, Teo J, Ray Chaudhuri K, et al
    Reply to: "Concerns Raised by Publication of Antonini et al., 'Outcome of Parkinson Disease Patients Affected by Covid-19'".
    Mov Disord. 2020;35:1298.
    PubMed    


  263. RAPHAEL KG
    Concerns Raised by Publication of Antonini et al., "Outcome of Parkinson Disease Patients Affected by Covid-19".
    Mov Disord. 2020;35:1297.
    PubMed    


    July 2020
  264. WEINTRAUB D, Chiang C, Kim HM, Wilkinson J, et al
    Clinical Follow-up of Parkinson's Disease With Newly Prescribed Quetiapine.
    Mov Disord. 2020 Jul 29. doi: 10.1002/mds.28193.
    PubMed    


  265. BHARAT V, Wang X
    Precision Neurology for Parkinson's Disease: Coupling Miro1-Based Diagnosis with Drug Discovery.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28194.
    PubMed     Abstract available


  266. HEILMAN PL, Wang EW, Lewis MM, Krzyzanowski S, et al
    Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28202.
    PubMed     Abstract available


  267. HAN G, Han J, Han K, Youn J, et al
    Visual Acuity and Development of Parkinson's Disease: A Nationwide Cohort Study.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28184.
    PubMed     Abstract available


  268. CHEN Y, Gu X, Ou R, Zhang L, et al
    Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
    Mov Disord. 2020 Jul 16. doi: 10.1002/mds.28191.
    PubMed     Abstract available


  269. LI C, Ou R, Chen Y, Gu X, et al
    Mutation Analysis of DNAJC Family for Early-Onset Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28203.
    PubMed     Abstract available


  270. SAN LUCIANO M, Tanner CM, Meng C, Marras C, et al
    Nonsteroidal Anti-Inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28189.
    PubMed     Abstract available


  271. HAMEDANI AG, Abraham DS, Maguire MG, Willis AW, et al
    Visual Impairment Is More Common in Parkinson's Disease and Is a Risk Factor for Poor Health Outcomes.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28182.
    PubMed     Abstract available


  272. PETRUCCI S, Ginevrino M, Trezzi I, Monfrini E, et al
    GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort.
    Mov Disord. 2020 Jul 13. doi: 10.1002/mds.28195.
    PubMed     Abstract available


  273. MESTRE TA, Freitas E, Basndwah A, Lopez MR, et al
    Glycopyrrolate Improves Disability from Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial.
    Mov Disord. 2020 Jul 13. doi: 10.1002/mds.28196.
    PubMed     Abstract available


  274. KLATT-SCHREINER K, Valek L, Kang JS, Khlebtovsky A, et al
    High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease.
    Mov Disord. 2020 Jul 11. doi: 10.1002/mds.28186.
    PubMed     Abstract available


  275. DE FRANCESCO E, Terzaghi M, Storelli E, Magistrelli L, et al
    CD4+ T-Cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2020 Jul 10. doi: 10.1002/mds.28137.
    PubMed     Abstract available


  276. YING AF, Khan S, Wu Y, Jin A, et al
    Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study.
    Mov Disord. 2020 Jul 9. doi: 10.1002/mds.28173.
    PubMed     Abstract available


  277. PARKER JE, Martinez A, Deutsch GK, Prabhakar V, et al
    Safety of Plasma Infusions in Parkinson's Disease.
    Mov Disord. 2020 Jul 7. doi: 10.1002/mds.28198.
    PubMed     Abstract available


  278. DEN HEIJER JM, Cullen VC, Quadri M, Schmitz A, et al
    A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.
    Mov Disord. 2020 Jul 2. doi: 10.1002/mds.28112.
    PubMed     Abstract available


  279. ZETTERBERG H
    Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease?
    Mov Disord. 2020;35:1111-1112.
    PubMed    


  280. MACASKILL MR, Myall DJ, Shoorangiz R, Anderson TJ, et al
    Childbirth and Delayed Parkinson's Onset: A Reproducible Nonbiological Artifact of Societal Change.
    Mov Disord. 2020;35:1268-1271.
    PubMed     Abstract available


  281. CERRONI R, Pierantozzi M, Moleti A, Stefani A, et al
    Laterality of Auditory Dysfunction in Parkinson's Disease.
    Mov Disord. 2020;35:1283-1284.
    PubMed    


  282. POPAT RA, Nelson LM
    What Matters in Parkinson's Disease: Sex, Number of Children, or Birth Cohort?
    Mov Disord. 2020;35:1108-1110.
    PubMed    


  283. FRANGE C, Huebra Pimentel Filho L, Aguilar AC, Coelho FMS, et al
    Exercise for "Sleep Rehabilitation" in Parkinson's Disease.
    Mov Disord. 2020;35:1285.
    PubMed    


  284. AMARA AW, Wood KH, Joop A, Memon RA, et al
    Reply to: Exercise for "Sleep Rehabilitation" in Parkinson's Disease.
    Mov Disord. 2020;35:1286.
    PubMed    


  285. JAFARI Z, Kolb BE, Mohajerani MH
    Reply to a Letter by Dr. Stefani and Colleagues on: "Auditory Dysfunction in Parkinson's Disease".
    Mov Disord. 2020;35:1284-1285.
    PubMed    


  286. LERCHE S, Wurster I, Roben B, Zimmermann M, et al
    CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Mov Disord. 2020;35:1138-1144.
    PubMed     Abstract available


    June 2020
  287. AZIZ NA, Roos RAC, Pijl H
    Insulin Sensitivity in De Novo Parkinson's Disease: A Hyperinsulinemic-Euglycemic Clamp Study.
    Mov Disord. 2020 Jun 30. doi: 10.1002/mds.28181.
    PubMed    


  288. RAJAN R, Brennan L, Bloem BR, Dahodwala N, et al
    Integrated Care in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Jun 29. doi: 10.1002/mds.28097.
    PubMed     Abstract available


  289. KOBYLECKI C, Jones T, Lim CK, Miller C, et al
    Phenomenology and outcomes of in-patients with Parkinson's disease during COVID-19 pandemic.
    Mov Disord. 2020 Jun 24. doi: 10.1002/mds.28205.
    PubMed    


  290. RAMIREZ J, Dilliott AA, Binns MA, Breen DP, et al
    Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities.
    Mov Disord. 2020 Jun 23. doi: 10.1002/mds.28171.
    PubMed     Abstract available


  291. GIAGKOU N, Maraki MI, Yannakoulia M, Kosmidis MH, et al
    A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease.
    Mov Disord. 2020 Jun 22. doi: 10.1002/mds.28145.
    PubMed     Abstract available


  292. OJO OO, Abubakar SA, Iwuozo EU, Nwazor EO, et al
    The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a Collaborative Project.
    Mov Disord. 2020 Jun 19. doi: 10.1002/mds.28123.
    PubMed     Abstract available


  293. KOULI A, Williams-Gray CH
    Timing Is Everything: The T-Cell Response to alpha-Synuclein Is Maximal in Early Parkinson's.
    Mov Disord. 2020 Jun 19. doi: 10.1002/mds.28122.
    PubMed    


  294. SILVA-BATISTA C, de Lima-Pardini AC, Nucci MP, Coelho DB, et al
    A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28128.
    PubMed     Abstract available


  295. NISHIWAKI H, Ito M, Ishida T, Hamaguchi T, et al
    Meta-Analysis of Gut Dysbiosis in Parkinson's Disease.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28119.
    PubMed     Abstract available


  296. DONADIO V, Incensi A, Rizzo G, De Micco R, et al
    Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease with Orthostatic Hypotension.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28126.
    PubMed     Abstract available


  297. SCHIERDING W, Farrow S, Fadason T, Graham OEE, et al
    Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28144.
    PubMed     Abstract available


  298. CHOE CU, Niemann L, Englisch C, Petersen E, et al
    Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease.
    Mov Disord. 2020 Jun 17. doi: 10.1002/mds.28129.
    PubMed     Abstract available


  299. JANKOVIC J, Okun MS, Kordower JH
    Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease.
    Mov Disord. 2020 Jun 12. doi: 10.1002/mds.28187.
    PubMed    


  300. PURRI R, Brennan L, Rick J, Xie SX, et al
    Subjective Cognitive Complaint in Parkinson's Disease Patients with Normal Cognition: Canary in the Coal Mine?
    Mov Disord. 2020 Jun 10. doi: 10.1002/mds.28115.
    PubMed     Abstract available


  301. AIT WAHMANE S, Achbani A, Ouhaz Z, Elatiqi M, et al
    The possible protective role of alpha-synuclein against the SARS-CoV-2 infections in patients with Parkinson's disease.
    Mov Disord. 2020 Jun 9. doi: 10.1002/mds.28185.
    PubMed    


  302. HATTORI N, Kitabayashi H, Kanda T, Nomura T, et al
    A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease.
    Mov Disord. 2020 Jun 5. doi: 10.1002/mds.28095.
    PubMed     Abstract available


  303. MARINI K, Mahlknecht P, Tutzer F, Stockner H, et al
    Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort.
    Mov Disord. 2020 Jun 3. doi: 10.1002/mds.28127.
    PubMed     Abstract available


  304. VALE TC, Barbosa MT, Franca Resende EP, Silva LC, et al
    No Correlation Between White Matter Changes and Mild Parkinsonian Signs in Individuals Aged Older Than 75 Years.
    Mov Disord. 2020 Jun 3. doi: 10.1002/mds.28120.
    PubMed    


  305. FASANO A, Cereda E, Barichella M, Cassani E, et al
    COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy.
    Mov Disord. 2020 Jun 2. doi: 10.1002/mds.28176.
    PubMed     Abstract available


  306. POSTUMA RB
    Exercise and Sleep in Parkinson's Disease.
    Mov Disord. 2020;35:918-920.
    PubMed    


  307. MARTINEZ-FERNANDEZ R
    Letter to the Editor: "Subthalamic Nucleus Stimulation Impairs Motivation: Implication for Apathy in Parkinson's Disease".
    Mov Disord. 2020;35:1084.
    PubMed    


  308. GOETZ CG, Stebbins GT, Luo S
    Movement Disorder Society-Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era.
    Mov Disord. 2020;35:911.
    PubMed    


  309. VACHEZ Y, Carcenac C, Magnard R, Goff LK, et al
    Reply to: Letter to the Editor by Martinez-Fernandez.
    Mov Disord. 2020;35:1084-1085.
    PubMed    


    May 2020
  310. NG J, Cortes-Saladelafont E, Abela L, Termsarasab P, et al
    DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.
    Mov Disord. 2020 May 30. doi: 10.1002/mds.28063.
    PubMed     Abstract available


  311. MULDERS AEP, van der Velden RMJ, Drukker M, Broen MPG, et al
    Usability of the Experience Sampling Method in Parkinson's Disease on a Group and Individual Level.
    Mov Disord. 2020 May 30. doi: 10.1002/mds.28028.
    PubMed     Abstract available


  312. HALL DA, Nag S, Ouyang B, Bennett DA, et al
    Fragile X Gray Zone Alleles Are Associated With Signs of Parkinsonism and Earlier Death.
    Mov Disord. 2020 May 28. doi: 10.1002/mds.28086.
    PubMed     Abstract available


  313. FABBRI M, Zibetti M, Rizzone MG, Giannini G, et al
    Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson's Disease?
    Mov Disord. 2020 May 25. doi: 10.1002/mds.28091.
    PubMed     Abstract available


  314. CILIA R, Bonvegna S, Straccia G, Nico GA, et al
    Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study.
    Mov Disord. 2020 May 25. doi: 10.1002/mds.28170.
    PubMed     Abstract available


  315. SHALASH A, Roushdy T, Essam M, Fathy M, et al
    Mental health, physical activity and quality of life in Parkinson's disease during COVID-19 pandemic.
    Mov Disord. 2020 May 19. doi: 10.1002/mds.28134.
    PubMed    


  316. TURNER TH, Dale ML
    Inconsistent Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Ratings in the Parkinson's Progression Marker Initiative.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28108.
    PubMed    


  317. MILOSEVIC L, Scherer M, Cebi I, Guggenberger R, et al
    Online Mapping with the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28093.
    PubMed     Abstract available


  318. MARRAS C, Pequeno P, Austin PC, Gershon AS, et al
    Beta Agonists and Progression of Parkinson's Disease in Older Adults: A Retrospective Cohort Study.
    Mov Disord. 2020 May 15. doi: 10.1002/mds.28085.
    PubMed    


  319. CHRISTINE CW, Auinger P, Saleh N, Tian M, et al
    Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression.
    Mov Disord. 2020 May 14. doi: 10.1002/mds.28073.
    PubMed     Abstract available


  320. CRAIG CE, Jenkinson NJ, Brittain JS, Grothe MJ, et al
    Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease.
    Mov Disord. 2020 May 13. doi: 10.1002/mds.28051.
    PubMed     Abstract available


  321. HATTORI N, Mochizuki H, Hasegawa K, Nomoto M, et al
    Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease.
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28071.
    PubMed     Abstract available


  322. BOIKA AV
    A postCOVID-19 parkinsonism in the future?
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28117.
    PubMed    


  323. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Can the 2019 novel coronavirus cause Parkinson's disease?
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28118.
    PubMed    


  324. SALARI M, Zali A, Ashrafi F, Etemadifar M, et al
    Incidence of Anxiety in Parkinson's Disease during Coronavirus disease (COVID-19) pandemic.
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28116.
    PubMed    


  325. BOOT E, Mentzel TQ, Palmer LD, van Harten PN, et al
    Age-Related Parkinsonian Signs in Microdeletion 22q11.2.
    Mov Disord. 2020 May 9. doi: 10.1002/mds.28080.
    PubMed     Abstract available


  326. SCHNEIDER SA, Alcalay RN
    Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
    Mov Disord. 2020 May 7. doi: 10.1002/mds.28072.
    PubMed    


  327. UCHIDA Y, Kan H, Sakurai K, Inui S, et al
    Magnetic Susceptibility Associates with Dopaminergic Deficits and Cognition in Parkinson's Disease.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28077.
    PubMed     Abstract available


  328. FAN SP, Lee NC, Lin CH
    Novel Phenotype of 6p25 Deletion Syndrome Presenting Juvenile Parkinsonism and Brain Calcification.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28079.
    PubMed     Abstract available


  329. PETERS S, Gallo V, Vineis P, Middleton LT, et al
    Alcohol Consumption and Risk of Parkinson's Disease: Data from a Large Prospective European Cohort.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28039.
    PubMed     Abstract available


  330. HORN MA, Gulberti A, Gulke E, Buhmann C, et al
    A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28083.
    PubMed     Abstract available


  331. HIRSCH EC, Standaert DG
    Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28075.
    PubMed     Abstract available


  332. TAKESHIGE-AMANO H, Saiki S, Fujimaki M, Ueno SI, et al
    Shared Metabolic Profile of Caffeine in Parkinsonian Disorders.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28068.
    PubMed     Abstract available


  333. ARCHER DB, Mitchell T, Burciu RG, Yang J, et al
    Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28060.
    PubMed     Abstract available


  334. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28052.
    PubMed     Abstract available


  335. BONET-PONCE PHD L, Cookson MR
    Can Leucine-Rich Repeat Kinase 2 Inhibition Benefit GBA-Parkinson's Disease?
    Mov Disord. 2020;35:721-723.
    PubMed    


  336. KIM HJ, Jeon B
    Does Urinary Retention Discriminate Multiple System Atrophy From Parkinson's Disease?
    Mov Disord. 2020;35:901-902.
    PubMed    


  337. CHAUDHURI KR, Jenner P, Antonini A
    Dyskinesia Matters: But Not as Much as It Used to.
    Mov Disord. 2020;35:900-901.
    PubMed    


  338. HAUSER RA, Eidelberg D, Pahwa R, Riggare S, et al
    Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini.
    Mov Disord. 2020;35:901.
    PubMed    


  339. FANCIULLI A, Wenning GK
    Which Autonomic Features Distinguish Multiple System Atrophy and When.
    Mov Disord. 2020;35:902-903.
    PubMed    


  340. ZHANG W, Yang C
    Stem Cell Modeling: A Promising New Avenue for Young-Onset PD Research.
    Mov Disord. 2020;35:759.
    PubMed    


    April 2020
  341. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Mov Disord. 2020 Apr 30. doi: 10.1002/mds.28066.
    PubMed     Abstract available


  342. GALOPPIN M, Berroir P, Soucy JP, Suzuki Y, et al
    Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography.
    Mov Disord. 2020 Apr 30. doi: 10.1002/mds.28046.
    PubMed     Abstract available


  343. WILSON H, Pagano G, de Natale ER, Mansur A, et al
    Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease.
    Mov Disord. 2020 Apr 29. doi: 10.1002/mds.28064.
    PubMed     Abstract available


  344. ANTONINI A, Leta V, Teo J, Chaudhuri KR, et al
    Outcome of Parkinson's Disease patients affected by COVID-19.
    Mov Disord. 2020 Apr 29. doi: 10.1002/mds.28104.
    PubMed    


  345. LOPEZ AM, Trujillo P, Hernandez AB, Lin YC, et al
    Structural Correlates of the Sensorimotor Cerebellum in Parkinson's Disease and Essential Tremor.
    Mov Disord. 2020 Apr 28. doi: 10.1002/mds.28044.
    PubMed     Abstract available


  346. WILKE C, Dos Santos MCT, Schulte C, Deuschle C, et al
    Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease.
    Mov Disord. 2020 Apr 27. doi: 10.1002/mds.28026.
    PubMed     Abstract available


  347. PRASAD S, Aguirre-Padilla DH, Poon YY, Kalsi-Ryan S, et al
    Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1-Year Prospective Trial.
    Mov Disord. 2020 Apr 20. doi: 10.1002/mds.28065.
    PubMed    


  348. PHILLIPPS C, Longato N, Bereau M, Carriere N, et al
    Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive-Compulsive Behavior? A Cross-Sectional Study.
    Mov Disord. 2020 Apr 20. doi: 10.1002/mds.28053.
    PubMed    


  349. PRASAD S, Holla VV, Neeraja K, Surisetti BK, et al
    Parkinson's disease and COVID-19: Perceptions and implications in patients and caregivers.
    Mov Disord. 2020 Apr 17. doi: 10.1002/mds.28088.
    PubMed    


  350. YOO JE, Jang W, Shin DW, Jeong SM, et al
    Timed Up and Go Test and the Risk of Parkinson's Disease: A Nation-wide Retrospective Cohort Study.
    Mov Disord. 2020 Apr 15. doi: 10.1002/mds.28055.
    PubMed     Abstract available


  351. HOPFNER F, Mueller SH, Szymczak S, Junge O, et al
    Rare Variants in Specific Lysosomal Genes Are Associated with Parkinson's Disease.
    Mov Disord. 2020 Apr 8. doi: 10.1002/mds.28037.
    PubMed     Abstract available


  352. OLANOW CW, Standaert DG, Kieburtz K, Viegas T, et al
    Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
    Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28027.
    PubMed     Abstract available


  353. PAPA SM, Brundin P, Fung VSC, Kang UJ, et al
    Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders.
    Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28067.
    PubMed    


  354. KARL JA, Ouyang B, Goetz S, Metman LV, et al
    A Novel DBS Paradigm for Axial Features in Parkinson's Disease: A Randomized Crossover Study.
    Mov Disord. 2020 Apr 4. doi: 10.1002/mds.28048.
    PubMed     Abstract available


    March 2020
  355. VIEIRA SRL, Toffoli M, Campbell P, Schapira AHV, et al
    Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy.
    Mov Disord. 2020 Mar 27. doi: 10.1002/mds.28030.
    PubMed    


  356. FEARON C, Farrell MA
    Disease-Specific Strains of alpha-Synuclein in Multiple System Atrophy and Parkinson's Disease: But Why?
    Mov Disord. 2020 Mar 23. doi: 10.1002/mds.28035.
    PubMed    


  357. SVENNINGSSON P, Odin P, Dizdar N, Johansson A, et al
    A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
    Mov Disord. 2020 Mar 21. doi: 10.1002/mds.28020.
    PubMed     Abstract available


  358. DONZUSO G, Agosta F, Canu E, Filippi M, et al
    MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
    Mov Disord. 2020 Mar 17. doi: 10.1002/mds.28025.
    PubMed     Abstract available


  359. LEODORI G, Belvisi D, De Bartolo MI, Fabbrini A, et al
    Re-emergent Tremor in Parkinson's Disease: The Role of the Motor Cortex.
    Mov Disord. 2020 Mar 16. doi: 10.1002/mds.28022.
    PubMed     Abstract available


  360. HIRATA K, Hattori T, Kina S, Chen Q, et al
    Striatal Dopamine Denervation Impairs Gait Automaticity in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Mar 12. doi: 10.1002/mds.28024.
    PubMed     Abstract available


  361. PALERMO G, Giannoni S, Frosini D, Morganti R, et al
    Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study.
    Mov Disord. 2020 Mar 10. doi: 10.1002/mds.28008.
    PubMed     Abstract available


  362. SHIN C, Lim Y, Lim H, Ahn TB, et al
    Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease.
    Mov Disord. 2020 Mar 10. doi: 10.1002/mds.28016.
    PubMed     Abstract available


  363. NUTT JG, Curtze C, Hiller A, Anderson S, et al
    Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.
    Mov Disord. 2020 Mar 9. doi: 10.1002/mds.27993.
    PubMed     Abstract available


  364. WIJEYEKOON RS, Moore SF, Farrell K, Breen DP, et al
    Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.
    Mov Disord. 2020 Mar 4. doi: 10.1002/mds.28015.
    PubMed     Abstract available


  365. MOOSA S, Martinez-Fernandez R, Elias WJ, Del Alamo M, et al
    Reply to: Comment on "the role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease".
    Mov Disord. 2020;35:521-522.
    PubMed    


  366. XU Y, He Q, Wang W
    Comment on "The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease".
    Mov Disord. 2020;35:521.
    PubMed    


  367. CASTILLO-TORRES SA, Sanchez-Cardenas M, Soto-Rincon CA, Chavez-Luevanos B, et al
    Kidney dysfunction and risk of Parkinson's disease: The issue of equations and large numbers.
    Mov Disord. 2020;35:519.
    PubMed    


  368. NAM GE, Kim NH, Han K, Choi KM, et al
    Reply to: Kidney Dysfunction and Risk of Parkinson's Disease: The Issue of Equations and Large Number".
    Mov Disord. 2020;35:520.
    PubMed    


  369. HANUSKA J, Rusz J, Bezdicek O, Dusek P, et al
    Comment on "pro-saccades predict cognitive decline in Parkinson's disease: ICICLE-PD".
    Mov Disord. 2020;35:522.
    PubMed    


    February 2020
  370. CHUNG SJ, Kim HR, Jung JH, Lee PH, et al
    Identifying the Functional Brain Network of Motor Reserve in Early Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28012.
    PubMed     Abstract available


  371. AMARA AW, Wood KH, Joop A, Memon RA, et al
    Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28009.
    PubMed     Abstract available


  372. ELFIL M, Kamel S, Kandil M, Koo BB, et al
    Implications of the Gut Microbiome in Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28004.
    PubMed     Abstract available


  373. WILLIAMS NM, Hubbard L, Sandor C, Webber C, et al
    Genome-Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor.
    Mov Disord. 2020 Feb 20. doi: 10.1002/mds.28001.
    PubMed    


  374. MIRELMAN A, Hillel I, Rochester L, Del Din S, et al
    Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease.
    Mov Disord. 2020 Feb 20. doi: 10.1002/mds.28006.
    PubMed     Abstract available


  375. SIMUNI T, Brumm MC, Uribe L, Caspell-Garcia C, et al
    Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Mov Disord. 2020 Feb 19. doi: 10.1002/mds.27989.
    PubMed     Abstract available


  376. SINGLETON AB, Gasser T
    The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease.
    Mov Disord. 2020 Feb 17. doi: 10.1002/mds.27999.
    PubMed    


  377. JAFARI Z, Kolb BE, Mohajerani MH
    Auditory Dysfunction in Parkinson's Disease.
    Mov Disord. 2020 Feb 13. doi: 10.1002/mds.28000.
    PubMed     Abstract available


  378. SEO SH, Bacolla A, Yoo D, Koo YJ, et al
    Replication-Based Rearrangements Are a Common Mechanism for SNCA Duplication in Parkinson's Disease.
    Mov Disord. 2020 Feb 10. doi: 10.1002/mds.27998.
    PubMed     Abstract available


  379. LITTLE S, Brown P
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020 Feb 10. doi: 10.1002/mds.27996.
    PubMed     Abstract available


  380. KNOX MG, Adler CH, Shill HA, Driver-Dunckley E, et al
    Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment.
    Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27991.
    PubMed     Abstract available


  381. POWELL A, Muller AJ, O'Callaghan C, Sourty M, et al
    Dopamine and Functional Connectivity in Patients With Parkinson's Disease and Visual Hallucinations.
    Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27995.
    PubMed    


  382. PINTER D, Janszky J, Kovacs N
    Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study".
    Mov Disord. 2020;35:375.
    PubMed    


  383. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study".
    Mov Disord. 2020;35:376-377.
    PubMed    


  384. FOLTYNIE T, Athauda D
    Diabetes, BMI, and Parkinson's.
    Mov Disord. 2020;35:201-203.
    PubMed    


  385. PALMA JA
    Renal dysfunction might be a marker of cardiovascular dysautonomia in prodromal alpha-synucleinopathies.
    Mov Disord. 2020;35:374.
    PubMed    


  386. MAHATO AK, Kopra J, Renko JM, Visnapuu T, et al
    Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
    Mov Disord. 2020;35:245-255.
    PubMed     Abstract available


  387. RAPPEL P, Grosberg S, Arkadir D, Linetsky E, et al
    Theta-alpha oscillations characterize emotional subregion in the human ventral subthalamic nucleus.
    Mov Disord. 2020;35:337-343.
    PubMed     Abstract available


  388. MARTINEZ E, Pasquereau B, Saga Y, Metereau E, et al
    The anterior caudate nucleus supports impulsive choices triggered by pramipexole.
    Mov Disord. 2020;35:296-305.
    PubMed     Abstract available


  389. LEE JY, Ahn J, Oh S, Shin JY, et al
    Retina thickness as a marker of neurodegeneration in prodromal lewy body disease.
    Mov Disord. 2020;35:349-354.
    PubMed     Abstract available


    January 2020
  390. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Pierre D. and the first photographs of Parkinson's disease.
    Mov Disord. 2020 Jan 24. doi: 10.1002/mds.27965.
    PubMed    


  391. GANG M, Baba T, Hosokai Y, Nishio Y, et al
    Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
    Mov Disord. 2020 Jan 23. doi: 10.1002/mds.27988.
    PubMed     Abstract available


  392. BARTH AL, Schneider JS, Johnston TH, Hill MP, et al
    NYX-458 improves cognitive performance in a primate Parkinson's disease model.
    Mov Disord. 2020 Jan 22. doi: 10.1002/mds.27962.
    PubMed     Abstract available


  393. IWAKI H, Blauwendraat C, Makarious MB, Bandres-Ciga S, et al
    Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score.
    Mov Disord. 2020 Jan 20. doi: 10.1002/mds.27974.
    PubMed     Abstract available


  394. VIJAYAN S, Singh B, Ghosh S, Stell R, et al
    Brainstem ventilatory dysfunction: A plausible mechanism for dyspnea in Parkinson's Disease?
    Mov Disord. 2020 Jan 15. doi: 10.1002/mds.27932.
    PubMed     Abstract available


  395. VACHEZ Y, Carcenac C, Magnard R, Kerkerian-Le Goff L, et al
    Subthalamic nucleus stimulation impairs motivation: Implication for apathy in Parkinson's disease.
    Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27953.
    PubMed     Abstract available


  396. SAMPEDRO F, Marin-Lahoz J, Martinez-Horta S, Perez-Gonzalez R, et al
    CLU rs11136000 promotes early cognitive decline in Parkinson's disease.
    Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27949.
    PubMed     Abstract available


  397. WIRTH T, Mariani LL, Bergant G, Baulac M, et al
    Loss-of-function mutations in NR4A2 cause dopa-responsive dystonia Parkinsonism.
    Mov Disord. 2020 Jan 10. doi: 10.1002/mds.27982.
    PubMed     Abstract available


  398. JI S, Wang C, Qiao H, Gu Z, et al
    Decreased Penetrance of Parkinson's Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study.
    Mov Disord. 2020 Jan 8. doi: 10.1002/mds.27971.
    PubMed     Abstract available


  399. RANGO M, Dossi G, Squarcina L, Bonifati C, et al
    Brain mitochondrial impairment in early-onset Parkinson's disease with or without PINK1 mutation.
    Mov Disord. 2020 Jan 2. doi: 10.1002/mds.27946.
    PubMed     Abstract available


  400. SANTOS-LOBATO BL, Schumacher-Schuh AF, Tumas V
    Predictors of Motor Complications in Early Parkinson's Disease.
    Mov Disord. 2020;35:191-192.
    PubMed    


  401. BAIG F, Kelly MJ, Lawton MA, Ben-Shlomo Y, et al
    Reply to: "Predictors of motor complications in early Parkinson's disease".
    Mov Disord. 2020;35:193.
    PubMed    


  402. KIM HJ, Mason S, Foltynie T, Winder-Rhodes S, et al
    Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort.
    Mov Disord. 2020;35:185-190.
    PubMed     Abstract available


  403. BELLOMO G, Paciotti S, Gatticchi L, Parnetti L, et al
    The vicious cycle between alpha-synuclein aggregation and autophagic-lysosomal dysfunction.
    Mov Disord. 2020;35:34-44.
    PubMed     Abstract available


  404. PYATIGORSKAYA N, Yahia-Cherif L, Gaurav R, Ewenczyk C, et al
    Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Mov Disord. 2020;35:161-170.
    PubMed     Abstract available


  405. COUGHLIN DG, Hurtig HI, Irwin DJ
    Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
    Mov Disord. 2020;35:5-19.
    PubMed     Abstract available


  406. CHAUDHURI KR, Schrag A, Weintraub D, Rizos A, et al
    The movement disorder society nonmotor rating scale: Initial validation study.
    Mov Disord. 2020;35:116-133.
    PubMed     Abstract available


  407. RESPONDEK G, Grimm MJ, Piot I, Arzberger T, et al
    Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
    Mov Disord. 2020;35:171-176.
    PubMed     Abstract available


  408. ALCALAY RN, Hsieh F, Tengstrand E, Padmanabhan S, et al
    Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Mov Disord. 2020;35:134-141.
    PubMed     Abstract available


    December 2019
  409. GENOUD S, Senior AM, Hare DJ, Double KL, et al
    Meta-analysis of copper and iron in Parkinson's disease brain and biofluids.
    Mov Disord. 2019 Dec 31. doi: 10.1002/mds.27947.
    PubMed     Abstract available


  410. SCHINDLBECK KA, Lucas-Jimenez O, Tang CC, Morbelli S, et al
    Metabolic network abnormalities in drug-naive Parkinson's Disease.
    Mov Disord. 2019 Dec 24. doi: 10.1002/mds.27960.
    PubMed     Abstract available


  411. WHITE RL 3RD, Campbell MC, Yang D, Shannon W, et al
    Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naive Parkinson's Disease.
    Mov Disord. 2019 Dec 19. doi: 10.1002/mds.27942.
    PubMed     Abstract available


  412. HALL S, Janelidze S, Zetterberg H, Brix B, et al
    Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.
    Mov Disord. 2019 Dec 13. doi: 10.1002/mds.27950.
    PubMed     Abstract available


  413. WANG Z, Yan J, Wang X, Yuan Y, et al
    Transcranial ultrasound stimulation directly influences the cortical excitability of the motor cortex in Parkinsonian mice.
    Mov Disord. 2019 Dec 12. doi: 10.1002/mds.27952.
    PubMed     Abstract available


  414. CRESSATTI M, Juwara L, Galindez JM, Velly AM, et al
    Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27935.
    PubMed     Abstract available


  415. MONJE MHG, Blesa J, Garcia-Cabezas MA, Obeso JA, et al
    Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27921.
    PubMed     Abstract available


  416. RAVANIDIS S, Bougea A, Papagiannakis N, Maniati M, et al
    Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27928.
    PubMed     Abstract available


  417. COSENTINO C, Baccini M, Putzolu M, Ristori D, et al
    Effectiveness of Physiotherapy on Freezing of Gait in Parkinson's Disease: A Systematic Review and Meta-Analyses.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27936.
    PubMed     Abstract available


  418. NEVES MA, Bouca-Machado R, Guerreiro D, Canica V, et al
    Swimming Is Compromised in Parkinson's Disease Patients.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27918.
    PubMed     Abstract available


  419. DE LA CASA-FAGES B, Fernandez-Eulate G, Gamez J, Barahona-Hernando R, et al
    Reply to: "Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion".
    Mov Disord. 2019;34:1932-1933.
    PubMed    


  420. REDDY SP, Socal MP, Rieder CRM, Schumacher-Schuh AF, et al
    Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens.
    Mov Disord. 2019;34:1929-1930.
    PubMed    


  421. CHAUDHURI KR, Jenner P, Antonini A
    Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens".
    Mov Disord. 2019;34:1930-1931.
    PubMed    


  422. FINSTERER J
    Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion.
    Mov Disord. 2019;34:1931-1932.
    PubMed    


  423. OBESO JA
    Editor's Note: Deep Brain Stimulation and Functional Neurosurgery for Movement Disorders: Is the Current Cycle Waning?
    Mov Disord. 2019;34:1792-1794.
    PubMed    


    November 2019
  424. LOPEZ G, Steward A, Ryan E, Groden C, et al
    Clinical Evaluation of Sibling Pairs With Gaucher Disease Discordant for Parkinsonism.
    Mov Disord. 2019 Nov 30. doi: 10.1002/mds.27916.
    PubMed     Abstract available


  425. JEONG SM, Han K, Kim D, Rhee SY, et al
    Body mass index, diabetes, and the risk of Parkinson's disease.
    Mov Disord. 2019 Nov 30. doi: 10.1002/mds.27922.
    PubMed     Abstract available


  426. MORALES-BRICENO H, Fung VSC
    Enhancement of glycolysis: A potential disease-modifying strategy for Parkinson's disease.
    Mov Disord. 2019 Nov 29. doi: 10.1002/mds.27934.
    PubMed    


  427. DELGADO-ALVARADO M, Marano M, Santurtun A, Urtiaga-Gallano A, et al
    Nonpharmacological, Nonsurgical Treatments for Freezing of Gait in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2019 Nov 26. doi: 10.1002/mds.27913.
    PubMed     Abstract available


  428. KIM IY, Yang TO, Heath AK, Simpson RF, et al
    Alcohol intake and Parkinson's disease risk in the million women study.
    Mov Disord. 2019 Nov 26. doi: 10.1002/mds.27933.
    PubMed     Abstract available


  429. BETROUNI N, Lopes R, Defebvre L, Leentjens AFG, et al
    Texture features of magnetic resonance images: A marker of slight cognitive deficits in Parkinson's disease.
    Mov Disord. 2019 Nov 23. doi: 10.1002/mds.27931.
    PubMed     Abstract available


  430. MANNE S, Kondru N, Jin H, Anantharam V, et al
    alpha-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients.
    Mov Disord. 2019 Nov 23. doi: 10.1002/mds.27907.
    PubMed     Abstract available


  431. BARBE MT, Tonder L, Krack P, Debu B, et al
    Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications.
    Mov Disord. 2019 Nov 22. doi: 10.1002/mds.27892.
    PubMed     Abstract available


  432. DI CAPRIO V, Modugno N, Mancini C, Olivola E, et al
    Early-stage Parkinson's patients show selective impairment in reactive but not proactive inhibition.
    Mov Disord. 2019 Nov 21. doi: 10.1002/mds.27920.
    PubMed     Abstract available


  433. BAIANO C, Barone P, Trojano L, Santangelo G, et al
    Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: A meta-analysis.
    Mov Disord. 2019 Nov 19. doi: 10.1002/mds.27902.
    PubMed     Abstract available


  434. MERTSALMI TH, Pekkonen E, Scheperjans F
    Antibiotic exposure and risk of Parkinson's disease in finland: A nationwide case-control study.
    Mov Disord. 2019 Nov 18. doi: 10.1002/mds.27924.
    PubMed     Abstract available


  435. OOSTERVELD LP, Verberk IMW, Majbour NK, El-Agnaf OM, et al
    CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson's from controls.
    Mov Disord. 2019 Nov 18. doi: 10.1002/mds.27897.
    PubMed     Abstract available


  436. PAZ-ALONSO PM, Navalpotro-Gomez I, Boddy P, Dacosta-Aguayo R, et al
    Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27885.
    PubMed     Abstract available


  437. SIDRANSKY E, Arkadir D, Bauer P, Dinur T, et al
    Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse?
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27903.
    PubMed    


  438. FANCIULLI A, Goebel G, Lazzeri G, Granata R, et al
    Urinary retention discriminates multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27917.
    PubMed    


  439. GILBERT RM, Standaert DG
    Bridging the gaps: More inclusive research needed to fully understand Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27906.
    PubMed    


  440. GAJOS KZ, Reinecke K, Donovan M, Stephen CD, et al
    Computer Mouse Use Captures Ataxia and Parkinsonism, Enabling Accurate Measurement and Detection.
    Mov Disord. 2019 Nov 7. doi: 10.1002/mds.27915.
    PubMed     Abstract available


  441. LAWTON M, Baig F, Toulson G, Morovat A, et al
    Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort.
    Mov Disord. 2019 Nov 6. doi: 10.1002/mds.27888.
    PubMed     Abstract available


  442. PETRILLO S, Schirinzi T, Di Lazzaro G, D'Amico J, et al
    Systemic activation of Nrf2 pathway in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27878.
    PubMed     Abstract available


  443. HAQUE ME, Akther M, Jakaria M, Kim IS, et al
    Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27874.
    PubMed     Abstract available


  444. RAJPUT AH, Rajput EF, Bocking SM, Auer RN, et al
    Reply to: Parkinsonism in essential tremor cases: A clinicopathological study-were they really essential tremor?
    Mov Disord. 2019;34:1750.
    PubMed    


  445. DE PEDRO-CUESTA J, Martinez-Martin P, Calero M, Almazan-Isla J, et al
    Reconciling etiological views on Parkinson's disease.
    Mov Disord. 2019;34:1750-1752.
    PubMed    


  446. MULROY E, Latorre A, Bhatia KP
    Parkinsonism in essential tremor cases: A clinicopathological study-were they really essential tremor?
    Mov Disord. 2019;34:1749.
    PubMed    


  447. RUNDEK T, Shpiner DS, Margolesky J
    Perivascular spaces in basal ganglia - An innocent bystander in Parkinson's disease?
    Mov Disord. 2019;34:1585-1587.
    PubMed    


    October 2019
  448. GILAT M, Coeytaux Jackson A, Marshall NS, Hammond D, et al
    Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Randomised Controlled Trial.
    Mov Disord. 2019 Oct 31. doi: 10.1002/mds.27886.
    PubMed     Abstract available


  449. LERCHE S, Wurster I, Roeben B, Zimmermann M, et al
    Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles.
    Mov Disord. 2019 Oct 30. doi: 10.1002/mds.27884.
    PubMed     Abstract available


  450. BANDRES-CIGA S, Ahmed S, Sabir MS, Blauwendraat C, et al
    The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight.
    Mov Disord. 2019 Oct 29. doi: 10.1002/mds.27864.
    PubMed     Abstract available


  451. NOYCE AJ, Bandres-Ciga S, Kim J, Heilbron K, et al
    The Parkinson's Disease Mendelian Randomization Research Portal.
    Mov Disord. 2019 Oct 28. doi: 10.1002/mds.27873.
    PubMed     Abstract available


  452. HAYAKAWA H, Nakatani R, Ikenaka K, Aguirre C, et al
    Structurally distinct alpha-synuclein fibrils induce robust parkinsonian pathology.
    Mov Disord. 2019 Oct 23. doi: 10.1002/mds.27887.
    PubMed     Abstract available


  453. PRETEGIANI E, Vanegas-Arroyave N, FitzGibbon EJ, Hallett M, et al
    Evidence From Parkinson's Disease That the Superior Colliculus Couples Action and Perception.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27861.
    PubMed     Abstract available


  454. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27876.
    PubMed     Abstract available


  455. MORALES-BRICENO H, Mahant N, Ha AD, Chang FCF, et al
    Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27883.
    PubMed    


  456. KOLMANCIC K, Perellon-Alfonso R, Pirtosek Z, Rothwell JC, et al
    Sex differences in Parkinson's disease: A transcranial magnetic stimulation study.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27870.
    PubMed     Abstract available


  457. VAN DER VEEN S, Zutt R, Klein C, Marras C, et al
    Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27828.
    PubMed     Abstract available


  458. SACHELI MA, Neva JL, Lakhani B, Murray DK, et al
    Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27865.
    PubMed     Abstract available



  459. Abstracts of the 2019 International Congress of the Parkinson's Disease and Movement Disorders(R).
    Mov Disord. 2019;34 Suppl 2:S1-S930.
    PubMed    


  460. HONKANEN EA, Saari L, Orte K, Gardberg M, et al
    Reply to: The time delay between in vivo imaging and postmortem data poses a caveat on "no link" findings.
    Mov Disord. 2019;34:1580-1581.
    PubMed    


  461. PIFL C
    The time delay between in vivo imaging and postmortem data poses a caveat on "no link" findings.
    Mov Disord. 2019;34:1579-1580.
    PubMed    


    September 2019
  462. BOUTHOUR W, Bereau M, Kibleur A, Zacharia A, et al
    Dyskinesia-inducing lead contacts optimize outcome of subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27853.
    PubMed     Abstract available


  463. DAYAL V, Grover T, Tripoliti E, Milabo C, et al
    Short Versus Conventional Pulse-Width Deep Brain Stimulation in Parkinson's Disease: A Randomized Crossover Comparison.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27863.
    PubMed     Abstract available


  464. LEE PC, Artaud F, Cormier-Dequaire F, Rascol O, et al
    Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2019 Sep 13. doi: 10.1002/mds.27854.
    PubMed     Abstract available


  465. IWAKI H, Blauwendraat C, Leonard HL, Kim JJ, et al
    Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.
    Mov Disord. 2019 Sep 10. doi: 10.1002/mds.27845.
    PubMed     Abstract available


  466. SU TH, Yang HC, Tseng TC, Chou SW, et al
    Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism.
    Mov Disord. 2019 Sep 10. doi: 10.1002/mds.27848.
    PubMed     Abstract available


  467. WONG YC, Luk K, Purtell K, Burke Nanni S, et al
    Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27823.
    PubMed     Abstract available


  468. POTASHKIN J, Huang X, Becker C, Chen H, et al
    Understanding the links between cardiovascular disease and Parkinson's disease.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27836.
    PubMed     Abstract available


  469. AQUINO CC, Duffley G, Hedges DM, Vorwerk J, et al
    Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27839.
    PubMed     Abstract available


  470. MOHANA SUNDARAM S, Garg P
    The gut-brain axis in Parkinson's disease: A focus on the transport of alpha-Synuclein.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27842.
    PubMed    


  471. FISHMAN P, Lipsman N
    Focused ultrasound as an evolving therapy for Parkinson's disease.
    Mov Disord. 2019;34:1241-1242.
    PubMed    


    August 2019
  472. NISSEN SK, Shrivastava K, Schulte C, Otzen DE, et al
    Alterations in Blood Monocyte Functions in Parkinson's Disease.
    Mov Disord. 2019 Aug 26. doi: 10.1002/mds.27815.
    PubMed     Abstract available


  473. SILVA DE LIMA AL, Smits T, Darweesh SKL, Valenti G, et al
    Home-based monitoring of falls using wearable sensors in Parkinson's disease.
    Mov Disord. 2019 Aug 26. doi: 10.1002/mds.27830.
    PubMed     Abstract available


  474. TERROBA-CHAMBI C, Bruno V, Millar-Vernetti P, Bruce D, et al
    Design and validation of a new instrument to assess fear of falling in Parkinson's disease.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27820.
    PubMed     Abstract available


  475. GAL O, Polakova K, Hoskovcova M, Tomandl J, et al
    Pavement patterns can be designed to improve gait in Parkinson's disease patients.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27831.
    PubMed     Abstract available


  476. STUART S, Lawson RA, Yarnall AJ, Nell J, et al
    Pro-Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE-PD.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27813.
    PubMed     Abstract available


  477. GORGES M, Kuntz B, Del Tredici K, Schmidt DG, et al
    Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson's disease.
    Mov Disord. 2019 Aug 21. doi: 10.1002/mds.27814.
    PubMed     Abstract available


  478. DE LA CASA-FAGES B, Fernandez-Eulate G, Gamez J, Barahona-Hernando R, et al
    Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism.
    Mov Disord. 2019 Aug 21. doi: 10.1002/mds.27812.
    PubMed     Abstract available


  479. FOFFANI G, Trigo-Damas I, Pineda-Pardo JA, Blesa J, et al
    Focused ultrasound in Parkinson's disease: A twofold path toward disease modification.
    Mov Disord. 2019 Aug 14. doi: 10.1002/mds.27805.
    PubMed     Abstract available


  480. HEINZEL S, Berg D, Gasser T, Chen H, et al
    Update of the MDS research criteria for prodromal Parkinson's disease.
    Mov Disord. 2019 Aug 14. doi: 10.1002/mds.27802.
    PubMed     Abstract available


    July 2019
  481. MOLLENHAUER B, Caspell-Garcia CJ, Coffey CS, Taylor P, et al
    Longitudinal analyses of cerebrospinal fluid alpha-Synuclein in prodromal and early Parkinson's disease.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27806.
    PubMed     Abstract available


  482. HAQ IU, Snively BM, Sweadner KJ, Suerken CK, et al
    Revising rapid-onset dystonia-parkinsonism: Broadening indications for ATP1A3 testing.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27801.
    PubMed     Abstract available


  483. KARAKATSANI ME, Blesa J, Konofagou EE
    Blood-brain barrier opening with focused ultrasound in experimental models of Parkinson's disease.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27804.
    PubMed     Abstract available


  484. OZTURK M, Abosch A, Francis D, Wu J, et al
    Distinct subthalamic coupling in the ON state describes motor performance in Parkinson's disease.
    Mov Disord. 2019 Jul 26. doi: 10.1002/mds.27800.
    PubMed     Abstract available


  485. AGALLIU I, Ortega RA, Luciano MS, Mirelman A, et al
    Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Mov Disord. 2019 Jul 26. doi: 10.1002/mds.27807.
    PubMed     Abstract available


  486. BOI L, Pisanu A, Greig N, Scerba MT, et al
    Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Mov Disord. 2019 Jul 23. doi: 10.1002/mds.27799.
    PubMed     Abstract available


  487. TSUKITA K, Sakamaki-Tsukita H, Tanaka K, Suenaga T, et al
    Value of in vivo alpha-synuclein deposits in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2019 Jul 19. doi: 10.1002/mds.27794.
    PubMed     Abstract available


  488. PARK YW, Shin NY, Chung SJ, Kim J, et al
    Magnetic Resonance Imaging-Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2019 Jul 19. doi: 10.1002/mds.27798.
    PubMed     Abstract available


  489. MARAKI MI, Stefanis L, Yannakoulia M, Kosmidis MH, et al
    Motor function and the probability of prodromal Parkinson's disease in older adults.
    Mov Disord. 2019 Jul 17. doi: 10.1002/mds.27792.
    PubMed     Abstract available


  490. PRANGE S, Metereau E, Maillet A, Lhommee E, et al
    Early limbic microstructural alterations in apathy and depression in de novo Parkinson's disease.
    Mov Disord. 2019 Jul 15. doi: 10.1002/mds.27793.
    PubMed     Abstract available


  491. MOREAU C, Pinto S
    Misconceptions about speech impairment in Parkinson's disease.
    Mov Disord. 2019 Jul 15. doi: 10.1002/mds.27791.
    PubMed    


  492. MOOSA S, Martinez-Fernandez R, Elias WJ, Del Alamo M, et al
    The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27779.
    PubMed     Abstract available


  493. EVERS LJW, Krijthe JH, Meinders MJ, Bloem BR, et al
    Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27790.
    PubMed     Abstract available


  494. OERTEL WH, Henrich MT, Janzen A, Geibl FF, et al
    The locus coeruleus: Another vulnerability target in Parkinson's disease.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27785.
    PubMed    


  495. KELLY MJ, Lawton MA, Baig F, Ruffmann C, et al
    Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
    Mov Disord. 2019 Jul 8. doi: 10.1002/mds.27783.
    PubMed     Abstract available


  496. CARROLL CB, Wyse RKH, Grosset DG
    Statins and Parkinson's: A complex interaction.
    Mov Disord. 2019;34:934-935.
    PubMed    


  497. MORALES-BRICENO H, Fung VSC
    You shall not pass! Gut bacteria can convert levodopa to dopamine.
    Mov Disord. 2019;34:986.
    PubMed    


  498. LATORRE A, Rocchi L, Berardelli A, Bhatia KP, et al
    The interindividual variability of transcranial magnetic stimulation effects: Implications for diagnostic use in movement disorders.
    Mov Disord. 2019;34:936-949.
    PubMed     Abstract available


  499. HINKLE JT, Dawson VL, Dawson TM
    The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.
    Mov Disord. 2019;34:959-969.
    PubMed     Abstract available


  500. KRISMER F, Seppi K, Gobel G, Steiger R, et al
    Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis.
    Mov Disord. 2019;34:1041-1048.
    PubMed     Abstract available


    June 2019
  501. MULLIN S, Beavan M, Bestwick J, McNeill A, et al
    Evolution and clustering of prodromal parkinsonian features in GBA1 carriers.
    Mov Disord. 2019 Jun 28. doi: 10.1002/mds.27775.
    PubMed     Abstract available


  502. VILA M
    Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease.
    Mov Disord. 2019 Jun 28. doi: 10.1002/mds.27776.
    PubMed     Abstract available


  503. COLLIER TJ, Sortwell CE, Mercado NM, Steece-Collier K, et al
    Cell therapy for Parkinson's disease: Why it doesn't work every time.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27742.
    PubMed     Abstract available


  504. NG ASL, Tan YJ, Zhao Y, Saffari SE, et al
    SNCA Rep1 promoter variability influences cognition in Parkinson's disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27768.
    PubMed     Abstract available


  505. FERNANDEZ-SANTIAGO R, Martin-Flores N, Antonelli F, Cerquera C, et al
    SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27770.
    PubMed     Abstract available


  506. HONKANEN EA, Saari L, Orte K, Gardberg M, et al
    No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27777.
    PubMed     Abstract available


  507. WICHMANN T
    Changing views of the pathophysiology of Parkinsonism.
    Mov Disord. 2019 Jun 19. doi: 10.1002/mds.27741.
    PubMed     Abstract available


  508. MATARAZZO M, Arroyo-Gallego T, Montero P, Puertas-Martin V, et al
    Remote Monitoring of Treatment Response in Parkinson's Disease: The Habit of Typing on a Computer.
    Mov Disord. 2019 Jun 18. doi: 10.1002/mds.27772.
    PubMed     Abstract available


  509. BERGSLAND N, Zivadinov R, Schweser F, Hagemeier J, et al
    Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27730.
    PubMed     Abstract available


  510. RAJPUT AH, Rajput EF, Bocking SM, Auer RN, et al
    Parkinsonism in essential tremor cases: A clinicopathological study.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27729.
    PubMed     Abstract available


  511. DE MICCO R, Esposito F, di Nardo F, Caiazzo G, et al
    Sex-related pattern of intrinsic brain connectivity in drug-naive Parkinson's disease patients.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27725.
    PubMed     Abstract available


  512. PAGANO G, Niccolini F, Wilson H, Yousaf T, et al
    Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
    Mov Disord. 2019 Jun 3. doi: 10.1002/mds.27733.
    PubMed     Abstract available


  513. JABARKHEEL Z, Wagle Shukla A
    Essential requisites for rest tremor assessment in Parkinson's disease.
    Mov Disord. 2019;34:927-929.
    PubMed    


  514. TEIVE HAG, Camargo CHF, Munhoz RP
    Reply to: Early distinction of Parkinson variant multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019;34:929.
    PubMed    


  515. OBESO JA
    Editor's note: The origin of Parkinson's disease: The importance of environment and lifestyle.
    Mov Disord. 2019;34:799-800.
    PubMed    


  516. FERNAGUT PO
    Dopamine and eating behavior disorders in Parkinson's disease: A complex recipe.
    Mov Disord. 2019;34:767-768.
    PubMed    


  517. OLANOW CW
    Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less.
    Mov Disord. 2019;34:812-815.
    PubMed    


    May 2019
  518. HEISS JD, Lungu C, Hammoud DA, Herscovitch P, et al
    Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
    Mov Disord. 2019 May 30. doi: 10.1002/mds.27724.
    PubMed     Abstract available


  519. PARNETTI L, Bellomo G
    The issue of waste disposal in Parkinson's disease pathogenesis.
    Mov Disord. 2019 May 30. doi: 10.1002/mds.27734.
    PubMed    


  520. EVANS AH, Okai D, Weintraub D, Lim SY, et al
    Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27689.
    PubMed     Abstract available


  521. MILANESE C, Payan-Gomez C, Galvani M, Molano Gonzalez N, et al
    Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27723.
    PubMed     Abstract available


  522. LEWITT PA, Lipsman N, Kordower JH
    Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27722.
    PubMed     Abstract available


  523. SMYTH N, Skender E, David FJ, Munoz MJ, et al
    Endurance exercise reduces cortisol in Parkinson's disease with mild cognitive impairment.
    Mov Disord. 2019 May 20. doi: 10.1002/mds.27719.
    PubMed    


  524. MARRAS C, Canning CG, Goldman SM
    Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade.
    Mov Disord. 2019 May 15. doi: 10.1002/mds.27720.
    PubMed     Abstract available


  525. UCHIDA Y, Kan H, Sakurai K, Arai N, et al
    Voxel-based quantitative susceptibility mapping in Parkinson's disease with mild cognitive impairment.
    Mov Disord. 2019 May 15. doi: 10.1002/mds.27717.
    PubMed     Abstract available


  526. LI Q, Fernagut PO, Bezard E
    l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.
    Mov Disord. 2019 May 13. doi: 10.1002/mds.27715.
    PubMed    


  527. THOMASSON N, Pioli E, Friedel C, Monseur A, et al
    Engrailed-1 induces long-lasting behavior benefit in an experimental Parkinson primate model.
    Mov Disord. 2019 May 11. doi: 10.1002/mds.27714.
    PubMed    


  528. OBESO JA
    Editor's note: Prodromal Parkinson's disease.
    Mov Disord. 2019;34:664.
    PubMed    


  529. LI J, Dauer W
    Cholinergic interneurons drive maladaptive changes in thalamostriatal circuitry after dopamine depletion.
    Mov Disord. 2019;34:682.
    PubMed    


    April 2019
  530. NAM GE, Kim NH, Han K, Choi KM, et al
    Chronic renal dysfunction, proteinuria, and risk of Parkinson's disease in the elderly.
    Mov Disord. 2019 Apr 25. doi: 10.1002/mds.27704.
    PubMed     Abstract available


  531. MINEO D, Cacace F, Mancini M, Vannelli A, et al
    Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.
    Mov Disord. 2019 Apr 19. doi: 10.1002/mds.27683.
    PubMed     Abstract available


  532. CHAUDHURI KR, Jenner P, Antonini A
    Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Mov Disord. 2019 Apr 14. doi: 10.1002/mds.27691.
    PubMed    


  533. VAN DER ZEE S, Vallez Garcia D, Elsinga PH, Willemsen ATM, et al
    [(18) F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer.
    Mov Disord. 2019 Apr 12. doi: 10.1002/mds.27698.
    PubMed    


  534. CHEN Y, Cen Z, Zheng X, Pan Q, et al
    LRP10 in autosomal-dominant Parkinson's disease.
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27693.
    PubMed     Abstract available


  535. PETERSEN MS, Lophaven SN, Lynge E, Weihe P, et al
    What does migration between the faroe islands and denmark tell us about the etiology of Parkinson's disease?
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27692.
    PubMed    


  536. GRAFF S, Petkovic S
    Parkinson's disease: How do highly toxic alpha-Synuclein/PAR aggregates mediate neuronal cell death?
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27688.
    PubMed    


  537. BARBAGALLO G, Quattrone A
    Does levodopa have a disease-modifying effect in Parkinson's disease? Evidence from a delayed-start trial.
    Mov Disord. 2019 Apr 8. doi: 10.1002/mds.27686.
    PubMed    


  538. BLAUWENDRAAT C, Heilbron K, Vallerga CL, Bandres-Ciga S, et al
    Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and alpha-synuclein mechanisms.
    Mov Disord. 2019 Apr 7. doi: 10.1002/mds.27659.
    PubMed     Abstract available


  539. JEONG SM, Jang W, Shin DW
    Association of statin use with Parkinson's disease: Dose-response relationship.
    Mov Disord. 2019 Apr 2. doi: 10.1002/mds.27681.
    PubMed     Abstract available


  540. LI Y, Wang C, Wang J, Zhou Y, et al
    Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus.
    Mov Disord. 2019 Apr 2. doi: 10.1002/mds.27682.
    PubMed     Abstract available



  541. 32nd ANNUAL SYMPOSIUM ON ETIOLOGY, PATHOGENESIS, AND TREATMENT OF PARKINSON DISEASE AND OTHER MOVEMENT DISORDERS.
    Mov Disord. 2019;34.
    PubMed    


  542. KISHORE A, Ashok Kumar Sreelatha A, Sturm M, von-Zweydorf F, et al
    Understanding the role of genetic variability in LRRK2 in Indian population.
    Mov Disord. 2019;34:496-505.
    PubMed     Abstract available


    March 2019
  543. LANG S, Hanganu A, Gan LS, Kibreab M, et al
    Network basis of the dysexecutive and posterior cortical cognitive profiles in Parkinson's disease.
    Mov Disord. 2019 Mar 29. doi: 10.1002/mds.27674.
    PubMed     Abstract available


  544. POSTUMA RB, Berg D
    Prodromal Parkinson's Disease: The Decade Past, the Decade to Come.
    Mov Disord. 2019 Mar 28. doi: 10.1002/mds.27670.
    PubMed     Abstract available


  545. WEINTRAUB D
    Impulse control disorders in Parkinson's disease: A 20-year odyssey.
    Mov Disord. 2019 Mar 26. doi: 10.1002/mds.27668.
    PubMed    


  546. PRICE RJ, Fisher DG, Suk JS, Hanes J, et al
    Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier?
    Mov Disord. 2019 Mar 25. doi: 10.1002/mds.27675.
    PubMed    


  547. ESPAY AJ, Hausdorff JM, Sanchez-Ferro A, Klucken J, et al
    A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies.
    Mov Disord. 2019 Mar 22. doi: 10.1002/mds.27671.
    PubMed     Abstract available


  548. VIZCARRA JA, Sanchez-Ferro A, Maetzler W, Marsili L, et al
    The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.
    Mov Disord. 2019 Mar 22. doi: 10.1002/mds.27673.
    PubMed    


  549. ARLOTTI M, Palmisano C, Minafra B, Todisco M, et al
    Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient.
    Mov Disord. 2019 Mar 20. doi: 10.1002/mds.27657.
    PubMed    


  550. MORRIS R, Yarnall AJ, Hunter H, Taylor JP, et al
    Noninvasive vagus nerve stimulation to target gait impairment in Parkinson's disease.
    Mov Disord. 2019 Mar 19. doi: 10.1002/mds.27664.
    PubMed    


  551. GUO Y, Xu W, Liu FT, Li JQ, et al
    Modifiable risk factors for cognitive impairment in Parkinson's disease: A systematic review and meta-analysis of prospective cohort studies.
    Mov Disord. 2019 Mar 14. doi: 10.1002/mds.27665.
    PubMed     Abstract available


  552. MONDAL B, Choudhury S, Simon B, Baker MR, et al
    Noninvasive vagus nerve stimulation improves gait and reduces freezing of gait in Parkinson's disease.
    Mov Disord. 2019 Mar 14. doi: 10.1002/mds.27662.
    PubMed    


  553. DE HEMPTINNE C, Wang DD, Miocinovic S, Chen W, et al
    Pallidal thermolesion unleashes gamma oscillations in the motor cortex in Parkinson's disease.
    Mov Disord. 2019 Mar 13. doi: 10.1002/mds.27658.
    PubMed     Abstract available


  554. KANG UJ, Boehme AK, Fairfoul G, Shahnawaz M, et al
    Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.
    Mov Disord. 2019 Mar 6. doi: 10.1002/mds.27646.
    PubMed     Abstract available


  555. MAGHZI H, Hogg EJ, Tan E, Pagano G, et al
    Adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Mov Disord. 2019;34:442.
    PubMed    


  556. BREEN DP, Halliday GM, Lang AE
    Gut-brain axis and the spread of alpha-synuclein pathology: Vagal highway or dead end?
    Mov Disord. 2019;34:307-316.
    PubMed     Abstract available


  557. ARENS J, Storzer L, Hirschmann J, Dalal SS, et al
    Freezing of gait does not modulate beta oscillations in mesial cortical motor areas.
    Mov Disord. 2019;34:436.
    PubMed    


    February 2019
  558. FARRER MJ, Follett J
    Endosomal trafficking leads the way in Parkinson's disease.
    Mov Disord. 2019 Feb 27. doi: 10.1002/mds.27647.
    PubMed    


  559. ALCALAY RN, Mallett V, Vanderperre B, Tavassoly O, et al
    SMPD1 mutations, activity, and alpha-synuclein accumulation in Parkinson's disease.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27642.
    PubMed     Abstract available


  560. LIN CH, Chen PL, Tai CH, Lin HI, et al
    A clinical and genetic study of early-onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and next-generation sequencing.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27633.
    PubMed     Abstract available


  561. FANCIULLI A, Goebel G, Lazzeri G, Scherfler C, et al
    Early distinction of Parkinson-variant multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27635.
    PubMed    


  562. IKEDA A, Shimada H, Nishioka K, Takanashi M, et al
    Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features.
    Mov Disord. 2019 Feb 17. doi: 10.1002/mds.27623.
    PubMed     Abstract available


  563. QUATTRONE A, Morelli M, Vescio B, Nigro S, et al
    Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.
    Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27621.
    PubMed     Abstract available


  564. DIEDERICH NJ, James Surmeier D, Uchihara T, Grillner S, et al
    Parkinson's disease: Is it a consequence of human brain evolution?
    Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27628.
    PubMed    


  565. SCHRAG A, Anastasiou Z, Ambler G, Noyce A, et al
    Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentations.
    Mov Disord. 2019 Feb 8. doi: 10.1002/mds.27616.
    PubMed     Abstract available


  566. YSSELSTEIN D, Shulman JM, Krainc D
    Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.
    Mov Disord. 2019 Feb 6. doi: 10.1002/mds.27631.
    PubMed     Abstract available


  567. DAFSARI HS, Martinez-Martin P, Rizos A, Trost M, et al
    EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
    Mov Disord. 2019 Feb 4. doi: 10.1002/mds.27626.
    PubMed     Abstract available


  568. HENDERSHOTT TR, Zhu D, Llanes S, Zabetian CP, et al
    Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
    Mov Disord. 2019;34:285-291.
    PubMed     Abstract available


  569. ROSS GW, Abbott RD, Petrovitch H, Duda JE, et al
    Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology.
    Mov Disord. 2019;34:228-235.
    PubMed     Abstract available


  570. SEBILLE SB, Rolland AS, Faillot M, Perez-Garcia F, et al
    Normal and pathological neuronal distribution of the human mesencephalic locomotor region.
    Mov Disord. 2019;34:218-227.
    PubMed     Abstract available


    January 2019
  571. HUANG X, Sterling NW, Du G, Sun D, et al
    Brain cholesterol metabolism and Parkinson's disease.
    Mov Disord. 2019 Jan 25. doi: 10.1002/mds.27609.
    PubMed     Abstract available


  572. ATKINSON-CLEMENT C, Cavazzini E, Zenon A, Witjas T, et al
    Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.
    Mov Disord. 2019 Jan 25. doi: 10.1002/mds.27625.
    PubMed     Abstract available


  573. BLESA J, Vila M
    Parkinson disease, substantia nigra vulnerability, and calbindin expression: Enlightening the darkness?
    Mov Disord. 2019 Jan 24. doi: 10.1002/mds.27618.
    PubMed    


  574. BANDRES-CIGA S, Saez-Atienzar S, Bonet-Ponce L, Billingsley K, et al
    The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease.
    Mov Disord. 2019 Jan 24. doi: 10.1002/mds.27614.
    PubMed     Abstract available


  575. HOOGLAND J, Boel JA, de Bie RMA, Schmand BA, et al
    Risk of Parkinson's disease dementia related to level I MDS PD-MCI.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27617.
    PubMed     Abstract available


  576. SEPPI K, Ray Chaudhuri K, Coelho M, Fox SH, et al
    Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27602.
    PubMed     Abstract available


  577. WARREN OLANOW C, Torti M, Kieburtz K, Leinonen M, et al
    Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27610.
    PubMed     Abstract available


  578. MARRAS C, Obeso JA
    We are what we eat - editors' note on the role of diet in Parkinson's disease.
    Mov Disord. 2019;34:1.
    PubMed    


  579. PAUL KC, Chuang YH, Shih IF, Keener A, et al
    The association between lifestyle factors and Parkinson's disease progression and mortality.
    Mov Disord. 2019;34:58-66.
    PubMed     Abstract available


  580. ASCHERIO A, Schwarzschild MA
    Lifestyle and Parkinson's disease progression.
    Mov Disord. 2019;34:7-8.
    PubMed    


  581. GRONICH N, Auriel E, Lavi I, Rennert G, et al
    Reply to: From beta-blockers to Parkinson's disease in respect of essential tremor.
    Mov Disord. 2019;34:154.
    PubMed    



  582. Retraction: 'Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients,' by Sato Y., Honda Y., Iwamoto, J., Kanoko, T., and Satoh, K.
    Mov Disord. 2019;34:156.
    PubMed    


  583. VOGELNIK K, Kojovic M
    From beta-blockers to Parkinson's disease in respect of essential tremor.
    Mov Disord. 2019;34:153.
    PubMed    


  584. RICCIARDI L, Sorbera C, Barbuto M, Morgante F, et al
    Sleep disturbances are mainly improved by deep brain stimulation of the subthalamic nucleus.
    Mov Disord. 2019;34:154-155.
    PubMed    


  585. HOMAYOON N, Pirpamer L, Franthal S, Katschnig-Winter P, et al
    Nigral iron deposition in common tremor disorders.
    Mov Disord. 2019;34:129-132.
    PubMed     Abstract available


  586. WHITWELL JL, Tosakulwong N, Schwarz CG, Botha H, et al
    MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.
    Mov Disord. 2019;34:105-113.
    PubMed     Abstract available


  587. HARRIS M, Steele J, Williams R, Pinkston J, et al
    MRI-guided laser interstitial thermal thalamotomy for medically intractable tremor disorders.
    Mov Disord. 2019;34:124-129.
    PubMed     Abstract available


  588. FISCHER DL, Sortwell CE
    BDNF provides many routes toward STN DBS-mediated disease modification.
    Mov Disord. 2019;34:22-34.
    PubMed     Abstract available


  589. HARMSEN IE, Lee DJ, Dallapiazza RF, De Vloo P, et al
    Ultra-high-frequency deep brain stimulation at 10,000 Hz improves motor function.
    Mov Disord. 2019;34:146-148.
    PubMed    


    December 2018
  590. LANGLEY J, He N, Huddleston DE, Chen S, et al
    Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27608.
    PubMed     Abstract available


  591. BONANNI L
    The democratic aspect of machine learning: Limitations and opportunities for Parkinson's disease.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27600.
    PubMed    


  592. KIM JJ, Bandres-Ciga S
    The appendix and the risk of Parkinson's disease: Appended notes on correlation and causation.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27599.
    PubMed    


  593. ATASHRAZM F, Hammond D, Perera G, Bolliger MF, et al
    LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27601.
    PubMed     Abstract available


  594. MORGANTE F, Valente EM
    LRP10: A novel disease gene bridging Parkinson's disease and dementia with Lewy body.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27593.
    PubMed    


  595. MARTINEZ-MARTIN P, Macaulay D, Jalundhwala YJ, Mu F, et al
    The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States.
    Mov Disord. 2018 Dec 27. doi: 10.1002/mds.27579.
    PubMed     Abstract available


  596. BARICHELLA M, Severgnini M, Cilia R, Cassani E, et al
    Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism.
    Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27581.
    PubMed     Abstract available


  597. JOHNSTON TH, Geva M, Steiner L, Orbach A, et al
    Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27565.
    PubMed     Abstract available


  598. STARHOF C, Hejl AM, Heegaard NHH, Carlsen AL, et al
    The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.
    Mov Disord. 2018 Dec 17. doi: 10.1002/mds.27542.
    PubMed     Abstract available


  599. CHUNG SJ, Jeon S, Yoo HS, Yoon JH, et al
    Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27580.
    PubMed    


  600. TRINH J, Lohmann K, Baumann H, Balck A, et al
    Utility and implications of exome sequencing in early-onset Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27559.
    PubMed     Abstract available


  601. BEJR-KASEM H, Pagonabarraga J, Martinez-Horta S, Sampedro F, et al
    Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27557.
    PubMed     Abstract available


  602. ASSAF F, Schiller Y
    A chemogenetic approach for treating experimental Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27554.
    PubMed     Abstract available


  603. GARGOURI F, Gallea C, Mongin M, Pyatigorskaya N, et al
    Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27561.
    PubMed     Abstract available


    November 2018
  604. CUI SS, Du JJ, Liu SH, Meng J, et al
    Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27569.
    PubMed     Abstract available


  605. IRMEN F, Horn A, Meder D, Neumann WJ, et al
    Sensorimotor subthalamic stimulation restores risk-reward trade-off in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27576.
    PubMed     Abstract available


  606. JANKOVIC J
    Pathogenesis-targeted therapeutic strategies in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27534.
    PubMed    


  607. KRISTIANSEN M, Maple-Grodem J, Alves G, Arepalli S, et al
    A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27555.
    PubMed    


  608. MOLLENHAUER B, Zimmermann J, Sixel-Doring F, Focke NK, et al
    Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mov Disord. 2018 Nov 23. doi: 10.1002/mds.27492.
    PubMed     Abstract available


  609. SANJARI MOGHADDAM H, Aarabi MH
    Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Mov Disord. 2018 Nov 19. doi: 10.1002/mds.27509.
    PubMed    


  610. DARVISH H, Bravo P, Tafakhori A, Azcona LJ, et al
    Identification of a large homozygous VPS13C deletion in a patient with early-onset Parkinsonism.
    Mov Disord. 2018 Nov 19. doi: 10.1002/mds.27516.
    PubMed    


  611. CORMIER-DEQUAIRE F, Bekadar S, Anheim M, Lebbah S, et al
    Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.
    Mov Disord. 2018 Nov 16. doi: 10.1002/mds.27519.
    PubMed     Abstract available


  612. LOFREDI R, Neumann WJ, Brucke C, Huebl J, et al
    Pallidal beta bursts in Parkinson's disease and dystonia.
    Mov Disord. 2018 Nov 15. doi: 10.1002/mds.27524.
    PubMed     Abstract available


  613. LYNCH WB, Tschumi CW, Sharpe AL, Branch SY, et al
    Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson's Model.
    Mov Disord. 2018 Nov 15. doi: 10.1002/mds.27541.
    PubMed     Abstract available


  614. MOHAMED IBRAHIM N, Ramli R, Koya Kutty S, Shah SA, et al
    Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus.
    Mov Disord. 2018 Nov 14. doi: 10.1002/mds.27526.
    PubMed    


  615. PICILLO M, Lizarraga KJ, Friesen EL, Chau H, et al
    Parkinsonism due to A53E alpha-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27506.
    PubMed     Abstract available


  616. FRIEDERICH A, Flinspach A, Suenkel U, Eschweiler GW, et al
    Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27539.
    PubMed    


  617. DELGADO-ALVARADO M, Dacosta-Aguayo R, Navalpotro-Gomez I, Gago B, et al
    Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27518.
    PubMed     Abstract available


  618. PUTZOLU M, Pelosin E, Ogliastro C, Lagravinese G, et al
    Anodal tDCS over prefrontal cortex improves dual-task walking in Parkinsonian patients with freezing.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27533.
    PubMed    


  619. KUIPERS DJS, Carr J, Bardien S, Thomas P, et al
    PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability.
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27501.
    PubMed     Abstract available


  620. POSTUMA RB
    Mediterranean diets and prodromal Parkinson's disease: A causal line, or a confound circle?
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27538.
    PubMed    


  621. ALBIN RL, Surmeier DJ, Tubert C, Sarter M, et al
    Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27540.
    PubMed    


  622. TANGNEY CC
    Diet to beat the odds of prodromal Parkinson's disease?
    Mov Disord. 2018 Nov 5. doi: 10.1002/mds.27520.
    PubMed    


  623. ESPAY AJ, Guskey MT, Norton JC, Coate B, et al
    Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
    Mov Disord. 2018 Nov 2. doi: 10.1002/mds.27488.
    PubMed     Abstract available


  624. OLANOW CW, Kenney C, Bandak S, Kieburtz KD, et al
    Adverse event reporting in clinical trials in Parkinson's Disease: Time for change.
    Mov Disord. 2018 Nov 1. doi: 10.1002/mds.27497.
    PubMed    


  625. SAMOTUS O, Jog M
    Reply to: Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1829-1830.
    PubMed    


  626. MEADOWS SM, Conti MM, Gross L, Chambers NE, et al
    Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Mov Disord. 2018;33:1740-1749.
    PubMed     Abstract available


  627. DE SOUZA CP, Dos Santos MGG, Hamani C, Fonoff ET, et al
    Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1828-1829.
    PubMed    


    October 2018
  628. SACHELI MA, Murray DK, Vafai N, Cherkasova MV, et al
    Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study.
    Mov Disord. 2018 Oct 30. doi: 10.1002/mds.27498.
    PubMed     Abstract available


  629. TRINH J, Zeldenrust FMJ, Huang J, Kasten M, et al
    Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
    Mov Disord. 2018 Oct 24. doi: 10.1002/mds.27527.
    PubMed     Abstract available


  630. HABETS JGV, Heijmans M, Kuijf ML, Janssen MLF, et al
    An update on adaptive deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Oct 24. doi: 10.1002.
    PubMed     Abstract available


  631. BETROUNI N, Delval A, Chaton L, Defebvre L, et al
    Electroencephalography-based machine learning for cognitive profiling in Parkinson's disease: Preliminary results.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27528.
    PubMed     Abstract available


  632. HUANG X, Ng SY, Chia NS, Acharyya S, et al
    Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27521.
    PubMed    


  633. WEERSINK JB, Eikelboom C, Dominguez Vega ZT, Maurits NM, et al
    Forward arm extension as a cue for gait initiation in Parkinson's patients.
    Mov Disord. 2018 Oct 17. doi: 10.1002/mds.27510.
    PubMed    


  634. TOSSERAMS A, Araujo R, Pringsheim T, Post B, et al
    Underrepresentation of women in Parkinson's disease trials.
    Mov Disord. 2018 Oct 11. doi: 10.1002/mds.27505.
    PubMed    


  635. MARAKI MI, Yannakoulia M, Stamelou M, Stefanis L, et al
    Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27489.
    PubMed     Abstract available


  636. VIRMANI T, Pillai L, Glover A, Doerhoff SM, et al
    Impaired step-length setting prior to turning in Parkinson's disease patients with freezing of gait.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27499.
    PubMed    


  637. FABER I, Martinez ARM, Martins CR Jr, Maia ML, et al
    SPG11-related parkinsonism: Clinical profile, molecular imaging and l-dopa response.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27491.
    PubMed     Abstract available


  638. HOLDEN SK, Medina LD, Hoyt B, Sillau SH, et al
    Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27487.
    PubMed     Abstract available


  639. BLAUWENDRAAT C, Bras JM, Nalls MA, Lewis PA, et al
    Coding variation in GBA explains the majority of the SYT11-GBA Parkinson's disease GWAS locus.
    Mov Disord. 2018 Oct 9. doi: 10.1002.
    PubMed    


  640. WALDTHALER J, Tsitsi P, Seimyr GO, Benfatto MN, et al
    Eye movements during reading in parkinson's disease: A pilot study.
    Mov Disord. 2018 Oct 8. doi: 10.1002.
    PubMed    


  641. SMITH AM, Depp C, Ryan BJ, Johnston GI, et al
    Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells.
    Mov Disord. 2018 Oct 7. doi: 10.1002.
    PubMed     Abstract available


  642. THALER A, Kozlovski T, Gurevich T, Bar-Shira A, et al
    Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27490.
    PubMed     Abstract available


  643. GREENAMYRE JT
    What's wrong with mitochondria in Parkinson's disease?
    Mov Disord. 2018 Oct 4. doi: 10.1002.
    PubMed    


  644. VAN DER VELDEN RMJ, Mulders AEP, Drukker M, Kuijf ML, et al
    Network analysis of symptoms in a Parkinson patient using experience sampling data: An n = 1 study.
    Mov Disord. 2018 Oct 4. doi: 10.1002.
    PubMed     Abstract available


  645. KOROS C, Simitsi A, Prentakis A, Beratis I, et al
    123I-FP-CIT SPECT [(123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T alpha-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27451.
    PubMed     Abstract available


  646. BEACH TG, Adler CH
    Importance of low diagnostic Accuracy for early Parkinson's disease.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27485.
    PubMed    


  647. BURCIU RG, Vaillancourt DE
    Imaging of Motor Cortex Physiology in Parkinson's Disease.
    Mov Disord. 2018 Oct 2. doi: 10.1002.
    PubMed     Abstract available



  648. Abstracts of the 2018 International Congress of Parkinson's Disease and Movement Disorders((R)).
    Mov Disord. 2018;33 Suppl 2:S1-S929.
    PubMed    


  649. DULOVIC M, Vos M
    Sleep dysfunction in Parkinson's disease: Novel molecular mechanism and implications for therapy.
    Mov Disord. 2018;33:1558-1559.
    PubMed    


  650. SCHRAG A
    Testing the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018;33:1518-1520.
    PubMed    


  651. WAGLE SHUKLA A, Fox SH
    Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.
    Mov Disord. 2018;33:1560.
    PubMed    


    September 2018
  652. BARTHEL C, van Helvert M, Haan R, Janssen AM, et al
    Visual cueing using laser shoes reduces freezing of gait in parkinson's patients at home.
    Mov Disord. 2018 Sep 29. doi: 10.1002/mds.27455.
    PubMed    


  653. RAMIG L, Halpern A, Spielman J, Fox C, et al
    Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27460.
    PubMed     Abstract available


  654. SICILIANO M, Trojano L, Santangelo G, De Micco R, et al
    Fatigue in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27461.
    PubMed     Abstract available


  655. FABBRI M, Ferreira JJ, Lees A, Stocchi F, et al
    Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Mov Disord. 2018 Sep 27. doi: 10.1002/mds.27475.
    PubMed     Abstract available


  656. VAN DER VELDEN RMJ, Broen MPG, Kuijf ML, Leentjens AFG, et al
    Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review.
    Mov Disord. 2018 Sep 17. doi: 10.1002/mds.27465.
    PubMed     Abstract available


  657. LOHLE M, Mangone G, Wolz M, Beuthien-Baumann B, et al
    Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
    Mov Disord. 2018 Sep 14. doi: 10.1002/mds.27466.
    PubMed     Abstract available


  658. LUBOMSKI M, Hayes M, Kennerson M, Ellis M, et al
    A novel Parkinson's disease risk variant, p. W378R, in the Gaucher's disease GBA gene.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed    


  659. HOOGLAND J, van Wanrooij LL, Boel JA, Goldman JG, et al
    Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Abstract available


  660. MESTRE TA
    Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed    


  661. CHARVIN D, Di Paolo T, Bezard E, Gregoire L, et al
    An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Mov Disord. 2018 Sep 14. doi: 10.1002/mds.27462.
    PubMed     Abstract available


  662. PALACIOS N, Hughes KC, Cereda E, Schwarzschild MA, et al
    Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Abstract available


  663. YORITAKA A, Ohtsuka C, Maeda T, Hirayama M, et al
    Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease.
    Mov Disord. 2018 Sep 12. doi: 10.1002/mds.27472.
    PubMed    


  664. NEVES MA, Bouca-Machado R, Guerreiro D, Canica V, et al
    Risk of drowning in people with Parkinson's disease.
    Mov Disord. 2018 Sep 12. doi: 10.1002/mds.27473.
    PubMed    


  665. PCHELINA S, Baydakova G, Nikolaev M, Senkevich K, et al
    Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations.
    Mov Disord. 2018 Sep 7. doi: 10.1002/mds.27393.
    PubMed     Abstract available


  666. GAARE JJ, Nido GS, Sztromwasser P, Knappskog PM, et al
    Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease.
    Mov Disord. 2018 Sep 5. doi: 10.1002.
    PubMed     Abstract available


  667. GUO L, Normando EM, Shah PA, De Groef L, et al
    Oculo-visual abnormalities in Parkinson's disease: Possible value as biomarkers.
    Mov Disord. 2018;33:1390-1406.
    PubMed     Abstract available


  668. VAILLANCOURT DE, Lehericy S
    Illuminating basal ganglia and beyond in Parkinson's disease.
    Mov Disord. 2018;33:1373-1375.
    PubMed    


  669. GRONICH N, Abernethy DR, Auriel E, Lavi I, et al
    beta2-adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Mov Disord. 2018;33:1465-1471.
    PubMed     Abstract available


    August 2018
  670. INOUE KI, Miyachi S, Nishi K, Okado H, et al
    Recruitment of calbindin into nigral dopamine neurons protects against MPTP-Induced parkinsonism.
    Mov Disord. 2018 Aug 30. doi: 10.1002.
    PubMed     Abstract available


  671. BERG D, Adler CH, Bloem BR, Chan P, et al
    Movement disorder society criteria for clinically established early Parkinson's disease.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27431.
    PubMed     Abstract available


  672. ROZANI V, Gurevich T, Giladi N, El-Ad B, et al
    Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27413.
    PubMed     Abstract available


  673. MESTRE TA, Shamy M, Benedetti F, Lang AE, et al
    Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27409.
    PubMed     Abstract available


  674. SIEURIN J, Andel R, Tillander A, Valdes EG, et al
    Occupational stress and risk for Parkinson's disease: A nationwide cohort study.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27439.
    PubMed     Abstract available


  675. DEFFAINS M, Iskhakova L, Katabi S, Israel Z, et al
    Longer beta oscillatory episodes reliably identify pathological subthalamic activity in Parkinsonism.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27418.
    PubMed     Abstract available


  676. WANNEVEICH M, Moisan F, Jacqmin-Gadda H, Elbaz A, et al
    Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010-2030) in France.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27447.
    PubMed     Abstract available


  677. POSTUMA RB, Poewe W, Litvan I, Lewis S, et al
    Validation of the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27362.
    PubMed     Abstract available


  678. LERCHE S, Liepelt-Scarfone I, Wurster I, Schulte C, et al
    Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease.
    Mov Disord. 2018 Aug 22. doi: 10.1002/mds.27427.
    PubMed     Abstract available


  679. WITEK N, Stebbins GT, Goetz CG
    What influences placebo and nocebo responses in Parkinson's disease?
    Mov Disord. 2018 Aug 22. doi: 10.1002/mds.27416.
    PubMed     Abstract available


  680. PHILLIPS MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, et al
    Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial.
    Mov Disord. 2018 Aug 11. doi: 10.1002/mds.27390.
    PubMed     Abstract available


  681. MESTRE TA, Ferreira JJ
    The placebo response in Parkinson's disease and other movement disorders.
    Mov Disord. 2018;33:1193-1194.
    PubMed    


  682. SKORVANEK M, Gelpi E, Mechirova E, Ladomirjakova Z, et al
    alpha-Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa.
    Mov Disord. 2018;33:1366-1368.
    PubMed    


  683. FERREIRA JJ, Trenkwalder C, Mestre TA
    Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?
    Mov Disord. 2018;33:1228-1235.
    PubMed     Abstract available


  684. QUATTRONE A, Barbagallo G, Cerasa A, Stoessl AJ, et al
    Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
    Mov Disord. 2018;33:1213-1227.
    PubMed     Abstract available


    July 2018
  685. PITCHER TL, Myall DJ, Pearson JF, Lacey CJ, et al
    Parkinson's disease across ethnicities: A nationwide study in New Zealand.
    Mov Disord. 2018 Jul 23. doi: 10.1002/mds.27389.
    PubMed     Abstract available


  686. GUPTA DK, Fahn S, Tatsuoka C, Kang UJ, et al
    Hoehn and Yahr stage 3 and postural stability item in the movement disorder society-unified Parkinson's disease rating scale.
    Mov Disord. 2018;33:1188-1189.
    PubMed    


  687. LOESCH DZ, Tassone F, Mellick GD, Horne M, et al
    Evidence for the role of FMR1 gray zone alleles as a risk factor for parkinsonism in females.
    Mov Disord. 2018;33:1178-1181.
    PubMed     Abstract available


  688. REYES CJ, Westenberger A
    An integrated OMICS approach unravels the elusive genetic cause of X-linked dystonia-parkinsonism.
    Mov Disord. 2018;33:1095.
    PubMed    


  689. SANTENS P, De Letter M, Lees AJ, Krack P, et al
    Crime and Parkinson's: The jury is out.
    Mov Disord. 2018;33:1092-1094.
    PubMed    


  690. SKORVANEK M, Martinez-Martin P, Stebbins GT, Goetz CG, et al
    Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Mov Disord. 2018;33:1189-1190.
    PubMed    


  691. RAKOVIC A, Domingo A, Grutz K, Kulikovskaja L, et al
    Genome editing in induced pluripotent stem cells rescues TAF1 levels in X-linked dystonia-parkinsonism.
    Mov Disord. 2018;33:1108-1118.
    PubMed     Abstract available


  692. EHGOETZ MARTENS KA, Shine JM, Walton CC, Georgiades MJ, et al
    Evidence for subtypes of freezing of gait in Parkinson's disease.
    Mov Disord. 2018;33:1174-1178.
    PubMed     Abstract available


    June 2018

  693. Abstracts of the 2nd Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2018;33.
    PubMed    


    May 2018
  694. SOMMERAUER M, Hansen AK, Parbo P, Fedorova TD, et al
    Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients.
    Mov Disord. 2018 May 24. doi: 10.1002/mds.27411.
    PubMed     Abstract available


  695. CHARLES KA, Naudet F, Bouali-Benazzouz R, Landry M, et al
    Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease.
    Mov Disord. 2018 May 18. doi: 10.1002/mds.27377.
    PubMed     Abstract available


  696. LI J, Ruskey JA, Arnulf I, Dauvilliers Y, et al
    Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27385.
    PubMed     Abstract available


  697. DU G, Lewis MM, Sica C, He L, et al
    Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27318.
    PubMed     Abstract available


  698. TANIGUCHI D, Hatano T, Kamagata K, Okuzumi A, et al
    Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27365.
    PubMed     Abstract available


  699. HELDMANN M, Heeren J, Klein C, Rauch L, et al
    Neuroimaging abnormalities in individuals exhibiting Parkinson's disease risk markers.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27313.
    PubMed     Abstract available


  700. MEROLA A, Romagnolo A, Lopiano L, Espay AJ, et al
    Reply to: "Autonomic dysfunction in Parkinson's disease: The hidden game changer?"
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27421.
    PubMed    


  701. DE PABLO-FERNANDEZ E, Warner TT
    Autonomic dysfunction in Parkinson's disease: The hidden game changer?
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27422.
    PubMed    


  702. BAUFRETON J, Milekovic T, Li Q, McGuire S, et al
    Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27404.
    PubMed     Abstract available


  703. LEWIS MM, Du G, Baccon J, Snyder AM, et al
    Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27381.
    PubMed     Abstract available


  704. ORTUNO-LIZARAN I, Beach TG, Serrano GE, Walker DG, et al
    Phosphorylated alpha-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.
    Mov Disord. 2018 May 8. doi: 10.1002/mds.27392.
    PubMed     Abstract available


  705. LEWITT PA
    Comment on 'Distinct metabolomic signature in cerebrospinal fluid in early Parkinson's disease' by Hiller et al.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27379.
    PubMed    


  706. CEDARBAUM JM
    Elephants, Parkinson's disease, and proof-of-concept clinical trials.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27398.
    PubMed    


  707. TREZZI JP, Hiller K, Mollenhauer B
    The importance of an independent validation cohort for metabolomics biomarker studies.
    Mov Disord. 2018;33:856.
    PubMed    


    April 2018
  708. LIPSMEIER F, Taylor KI, Kilchenmann T, Wolf D, et al
    Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27376.
    PubMed     Abstract available


  709. SARDI SP, Cedarbaum JM, Brundin P
    Targeted therapies for Parkinson's disease: From genetics to the clinic.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27414.
    PubMed     Abstract available


  710. HANGANU A, Houde JC, Fonov VS, Degroot C, et al
    White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease.
    Mov Disord. 2018 Apr 23. doi: 10.1002/mds.27364.
    PubMed     Abstract available


  711. LEFAIVRE SC, Brown MJN, Almeida QJ
    Does cerebellar overactivity contribute to gait and balance deficits in Parkinson's disease?
    Mov Disord. 2018 Apr 20. doi: 10.1002/mds.27396.
    PubMed    


  712. MESTRE TA, Pont-Sunyer C, Kausar F, Visanji NP, et al
    Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mov Disord. 2018 Apr 17. doi: 10.1002/mds.27272.
    PubMed     Abstract available


  713. CONTARINO MF, Marinus J, van Hilten JJ
    Does deep brain stimulation of the subthalamic nucleus prolong survival in Parkinson's Disease?
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27384.
    PubMed    


  714. FRIEDMAN JH
    Quetiapine for Parkinson's Disease psychosis: Evidence-based medicine versus expert belief: A case study.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27378.
    PubMed    


  715. LANG AE, Espay AJ
    Disease modification in Parkinson's Disease: Current approaches, challenges, and future considerations.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27360.
    PubMed     Abstract available


  716. KASTEN M, Hartmann C, Hampf J, Schaake S, et al
    Genotype-phenotype relations for the Parkinson's Disease genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27352.
    PubMed     Abstract available


  717. AMANAT M, Salehi M
    Glitazone in Parkinson's Disease.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27397.
    PubMed    


  718. SCOTT KM, Williams-Gray CH
    Targeting aged astrocytes may be a new therapeutic strategy in Parkinson's disease.
    Mov Disord. 2018 Apr 6. doi: 10.1002/mds.27387.
    PubMed    


    March 2018
  719. MACEROLLO A, Brown MJN
    Beta oscillations and indirect pathway spiny projecting neurons: A selective neuronal mechanism linked to Parkinsonian pathophysiology?
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27388.
    PubMed    


  720. WEIR S, Samnaliev M, Kuo TC, Tierney TS, et al
    Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27302.
    PubMed     Abstract available


  721. KORDOWER JH, Burke RE
    Disease modification for Parkinson's disease: Axonal regeneration and trophic factors.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27383.
    PubMed     Abstract available


  722. COSSU G, Melis M, Sarchioto M, Melis M, et al
    6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27391.
    PubMed     Abstract available


  723. LITVAN I, Kieburtz K, Troster AI, Aarsland D, et al
    Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27345.
    PubMed     Abstract available


  724. KADHIM S, Pringsheim T, Le A, Fiest KM, et al
    Validating screening tools for depression in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27371.
    PubMed    


  725. MOGHADDAM HS, Arabi MH
    Synaptotagmin-11 Is a novel hotspot in the pathogenesis of parkin-linked Parkinson's disease: New implications for clinical targeting.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27369.
    PubMed    


  726. HOUSER MC, Chang J, Factor SA, Molho ES, et al
    Stool immune profiles evince gastrointestinal inflammation in Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27326.
    PubMed     Abstract available


  727. SIMUNI T, Siderowf A, Lasch S, Coffey CS, et al
    Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27361.
    PubMed     Abstract available


  728. FOX SH, Katzenschlager R, Lim SY, Barton B, et al
    International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27372.
    PubMed     Abstract available


  729. FASANO A, De Vloo P, Llinas M, Hlasny E, et al
    Magnetic resonance imaging-guided focused ultrasound thalamotomy in Parkinson tremor: Reoperation after benefit decay.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27348.
    PubMed    


  730. ANTONINI A, Moro E, Godeiro C, Reichmann H, et al
    Medical and surgical management of advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27340.
    PubMed     Abstract available


  731. FERNANDEZ HH, Boyd JT, Fung VSC, Lew MF, et al
    Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27338.
    PubMed     Abstract available


  732. HEINZEL S, Kasten M, Behnke S, Vollstedt EJ, et al
    Age- and sex-related heterogeneity in prodromal Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27349.
    PubMed    


  733. WEINTRAUB D, Troster AI, Marras C, Stebbins G, et al
    Initial cognitive changes in Parkinson's disease.
    Mov Disord. 2018 Mar 15. doi: 10.1002/mds.27330.
    PubMed     Abstract available


  734. CARDOSO F
    Vitamin B12 and Parkinson's disease: What is the relationship?
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27366.
    PubMed    


  735. BECK G, Maehara S, Chang PL, Papa SM, et al
    A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27341.
    PubMed     Abstract available


  736. CHRISTINE CW, Auinger P, Joslin A, Yelpaala Y, et al
    Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson's disease.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27301.
    PubMed     Abstract available


  737. PALMA JA, Kaufmann H
    Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.
    Mov Disord. 2018;33:372-390.
    PubMed     Abstract available


  738. CHEN X, Scholz SW
    Identification of new alpha-synuclein regulator by nontraditional drug development pipeline.
    Mov Disord. 2018;33:402.
    PubMed    


    February 2018
  739. SONG W, Kothari V, Velly AM, Cressatti M, et al
    Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27328.
    PubMed     Abstract available


  740. GOLDMAN JG, Holden SK, Litvan I, McKeith I, et al
    Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27323.
    PubMed     Abstract available


  741. MORALES-BRICENO H, Sanchez-Hernandez BE, Meyer E, Kurian MA, et al
    Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27294.
    PubMed    


  742. CENCI MA, Crossman AR
    Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27337.
    PubMed     Abstract available


  743. MENG Y, Voisin MR, Suppiah S, Kalia SK, et al
    Is there a role for MR-guided focused ultrasound in Parkinson's disease?
    Mov Disord. 2018 Feb 24. doi: 10.1002/mds.27308.
    PubMed    


  744. WEIL RS, Schwarzkopf DS, Bahrami B, Fleming SM, et al
    Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo-perceptual deficits.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27311.
    PubMed     Abstract available


  745. PERAN P, Barbagallo G, Nemmi F, Sierra M, et al
    MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27307.
    PubMed     Abstract available


  746. ARGAUD S, Verin M, Sauleau P, Grandjean D, et al
    Facial emotion recognition in Parkinson's disease: A review and new hypotheses.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27305.
    PubMed     Abstract available


  747. FERNANDEZ-SANTIAGO R, Garrido A, Infante J, Gonzalez-Aramburu I, et al
    alpha-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27295.
    PubMed     Abstract available


  748. DAFSARI HS, Silverdale M, Strack M, Rizos A, et al
    Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2018 Feb 21. doi: 10.1002/mds.27283.
    PubMed     Abstract available


  749. FEDERICO A, Tinazzi M, Tamburin S
    MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27329.
    PubMed    


  750. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27339.
    PubMed    


  751. WYMAN-CHICK KA, Martin PK, Weintraub D, Sperling SA, et al
    Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27335.
    PubMed     Abstract available


  752. PARK JS, Koentjoro B, Klein C, Sue CM, et al
    Single heterozygous ATP13A2 mutations cause cellular dysfunction associated with Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27327.
    PubMed    


  753. SAMOTUS O, Parrent A, Jog M
    Spinal cord stimulation therapy for gait dysfunction in advanced Parkinson's disease patients.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.
    PubMed     Abstract available


  754. FAZIO P, Svenningsson P, Cselenyi Z, Halldin C, et al
    Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27316.
    PubMed     Abstract available


  755. BOUCA-MACHADO R, Lennaerts-Kats H, Bloem B, Ferreira JJ, et al
    Why palliative care applies to Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27309.
    PubMed    


  756. DAGAN M, Herman T, Harrison R, Zhou J, et al
    Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300.
    PubMed     Abstract available


  757. PALMA JA
    Autonomic dysfunction in Parkinson's disease and other synucleinopathies: Introduction to the series.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27347.
    PubMed    


  758. ABBASI N, Mohajer B, Abbasi S, Hasanabadi P, et al
    Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27284.
    PubMed     Abstract available


  759. MULAK A
    A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27304.
    PubMed    


  760. MAHLKNECHT P, Gasperi A, Djamshidian A, Kiechl S, et al
    Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27281.
    PubMed     Abstract available


  761. BAHIRAEE A, Ebrahimi R
    A noble pathological role for alpha-synuclein in triggering neurodegeneration of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27306.
    PubMed    


  762. CREED RB, Goldberg MS
    New developments in genetic rat models of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27296.
    PubMed     Abstract available


  763. WEINTRAUB D, Hamilton JL, Eberling J, Litvan I, et al
    At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27310.
    PubMed    


  764. LAGRAVINESE G, Pelosin E, Bonassi G, Carbone F, et al
    Gait initiation is influenced by emotion processing in Parkinson's disease patients with freezing.
    Mov Disord. 2018 Feb 2. doi: 10.1002/mds.27312.
    PubMed     Abstract available


  765. NAROS G, Grimm F, Weiss D, Gharabaghi A, et al
    Directional communication during movement execution interferes with tremor in Parkinson's disease.
    Mov Disord. 2018;33:251-261.
    PubMed     Abstract available


    January 2018
  766. NOYCE AJ, Dickson J, Rees RN, Bestwick JP, et al
    Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27282.
    PubMed     Abstract available


  767. MOREAU C, Duce JA, Rascol O, Devedjian JC, et al
    Iron as a therapeutic target for Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27275.
    PubMed    


  768. PAL G, Ouyang B, Verhagen L, Serrano G, et al
    Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27280.
    PubMed    


  769. CHEN V, Saez-Atienzar S
    A tango for two: Dopamine and alpha-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27248.
    PubMed    


  770. SAVICA R, Grossardt BR, Rocca WA, Bower JH, et al
    Parkinson disease with and without Dementia: A prevalence study and future projections.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27277.
    PubMed     Abstract available


  771. HIMMELBERG MM, West RJH, Wade AR, Elliott CJH, et al
    A perceptive plus in Parkinson's disease.
    Mov Disord. 2018 Jan 14. doi: 10.1002/mds.27240.
    PubMed    


  772. KIM IY, O'Reilly EJ, Hughes KC, Gao X, et al
    Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.
    Mov Disord. 2018 Jan 10. doi: 10.1002/mds.27279.
    PubMed     Abstract available


  773. GARCIA-SANZ P, Moratalla R
    The importance of cholesterol in Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27251.
    PubMed    


  774. GAO Y, Wilson GR, Stephenson SEM, Bozaoglu K, et al
    The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27270.
    PubMed     Abstract available


  775. AHMADI NS
    Mutant parkin-induced parkinsonism from an electrical point of view: Abnormal excitatory response to dopamine resolved after substitution.
    Mov Disord. 2018;33:71.
    PubMed    


  776. FASANO A, Lang AE, Espay AJ
    What is "essential" about essential tremor? A diagnostic placeholder.
    Mov Disord. 2018;33:58-61.
    PubMed    


  777. ALBANESE A
    Classifying tremor: Language matters.
    Mov Disord. 2018;33:3-4.
    PubMed    


  778. SCHEPERJANS F
    The prodromal microbiome.
    Mov Disord. 2018;33:5-7.
    PubMed    


    December 2017
  779. MEROLA A, Romagnolo A, Rosso M, Suri R, et al
    Autonomic dysfunction in Parkinson's disease: A prospective cohort study.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27268.
    PubMed     Abstract available


  780. MARRINAN SL, Otiker T, Vasist LS, Gibson RA, et al
    A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27259.
    PubMed     Abstract available


  781. BOWER JH, Grossardt BR, Rocca WA, Savica R, et al
    Prevalence of and indications for antipsychotic use in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27256.
    PubMed     Abstract available


  782. LIU Z, Tang B
    Novel Parkinson's disease risk loci identified through a meta-analysis of genome-wide association studies.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27276.
    PubMed    


  783. BOUTHOUR W, Wegrzyk J, Momjian S, Peron J, et al
    Short pulse width in subthalamic stimulation in Parkinson's disease: a randomized, double-blind study.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27265.
    PubMed     Abstract available


  784. ROOSEN DA, Singleton AB
    Leucine rich repeat kinase knockout (LRRK KO) mouse model: Linking pathological hallmarks of inherited and sporadic Parkinson's disease.
    Mov Disord. 2017 Dec 19. doi: 10.1002/mds.27267.
    PubMed    


  785. PICCONI B, Hernandez LF, Obeso JA, Calabresi P, et al
    Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Mov Disord. 2017 Dec 8. doi: 10.1002/mds.27261.
    PubMed     Abstract available


  786. GOLDMAN JG, Andrews H, Amara A, Naito A, et al
    Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27232.
    PubMed     Abstract available


  787. KIEBURTZ K, Katz R, Olanow CW
    New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27220.
    PubMed    


  788. FERNANDES HJR
    Beyond the lysosome: Cholesterol role on endoplasmic reticulum and lipid droplets in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27249.
    PubMed    


  789. PADMANABHAN S, Burke RE
    Induction of axon growth in the adult brain: A new approach to restoration in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27209.
    PubMed    


    November 2017
  790. LOZANO CS, Tam J, Lozano AM
    The changing landscape of surgery for Parkinson's Disease.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27228.
    PubMed     Abstract available


  791. BHATIA KP, Bain P, Bajaj N, Elble RJ, et al
    Consensus Statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27121.
    PubMed     Abstract available


  792. SVENSSON E, Henderson VW, Szepligeti S, Stokholm MG, et al
    Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study.
    Mov Disord. 2017 Nov 29. doi: 10.1002/mds.27253.
    PubMed     Abstract available


  793. BUARD I, Sciacca DM, Martin CS, Rogers S, et al
    Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Nov 27. doi: 10.1002/mds.27246.
    PubMed    


  794. TROPEA TF, Xie SX, Rick J, Chahine LM, et al
    APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27204.
    PubMed     Abstract available


  795. KOHSAKA M, Oeda T, Umemura A, Tomita S, et al
    Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27243.
    PubMed    


  796. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27233.
    PubMed     Abstract available


  797. KULIKOVSKAJA L, Seibler P
    Dopamine oxidation mediates a time-dependent pathological cascade in Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27262.
    PubMed    


  798. STEIGERWALD F, Timmermann L, Kuhn A, Schnitzler A, et al
    Pulse duration settings in subthalamic stimulation for Parkinson's disease.
    Mov Disord. 2017 Nov 22. doi: 10.1002/mds.27238.
    PubMed     Abstract available


  799. POCHARD C, Leclair-Visonneau L, Coron E, Neunlist M, et al
    Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27237.
    PubMed    


  800. WEAVER FM, Stroupe KT, Smith B, Gonzalez B, et al
    Survival in patients with Parkinson's disease after deep brain stimulation or medical management.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27235.
    PubMed     Abstract available


  801. DAFSARI HS, Reker P, Stalinski L, Silverdale M, et al
    Quality of life outcomes after subthalamic stimulation in Parkinson's disease depends on age.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27222.
    PubMed     Abstract available


  802. SYRKIN-NIKOLAU J, Neuville R, O'Day J, Anidi C, et al
    Coordinated reset vibrotactile stimulation shows prolonged improvement in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27223.
    PubMed    


  803. ELAHI E
    PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability.
    Mov Disord. 2017 Nov 16. doi: 10.1002/mds.27126.
    PubMed    


  804. HELMICH RC
    The cerebral basis of Parkinsonian tremor: A network perspective.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27224.
    PubMed     Abstract available


  805. GOETZ CG
    Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years?
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27214.
    PubMed    


  806. ARNALDI D, De Carli F, Fama F, Brugnolo A, et al
    Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27190.
    PubMed     Abstract available


  807. SCHNEIDER SA, Alcalay RN
    Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
    Mov Disord. 2017;32:1504-1523.
    PubMed     Abstract available


  808. SCHAPIRA AH
    What would James Parkinson think? A virtual dialogue on factors influencing the development of Parkinson's disease.
    Mov Disord. 2017;32:1499-1500.
    PubMed    


    October 2017
  809. SOHAIL S, Yu L, Schneider JA, Bennett DA, et al
    Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27200.
    PubMed     Abstract available


  810. LI W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, et al
    11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27183.
    PubMed     Abstract available


  811. METEREAU E, Beaudoin-Gobert M, Duperrier S, Thobois S, et al
    Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
    Mov Disord. 2017 Oct 27. doi: 10.1002/mds.27201.
    PubMed     Abstract available


  812. FASANO A, Canning CG, Hausdorff JM, Lord S, et al
    Falls in Parkinson's disease: A complex and evolving picture.
    Mov Disord. 2017 Oct 25. doi: 10.1002/mds.27195.
    PubMed     Abstract available


  813. WEINTRAUB D, Chahine LM, Hawkins KA, Siderowf A, et al
    Cognition and the course of prodromal Parkinson's disease.
    Mov Disord. 2017 Oct 24. doi: 10.1002/mds.27189.
    PubMed     Abstract available


  814. FENGLER S, Liepelt-Scarfone I, Brockmann K, Schaffer E, et al
    Cognitive changes in prodromal Parkinson's disease: A review.
    Mov Disord. 2017 Oct 5. doi: 10.1002/mds.27135.
    PubMed     Abstract available


  815. ASCHERIO A, Schwarzschild MA
    Dietary antioxidants and Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27194.
    PubMed    


  816. SAEED U, Masellis M
    Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27171.
    PubMed    


  817. MACLEOD AD, Dalen I, Tysnes OB, Larsen JP, et al
    Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27177.
    PubMed     Abstract available


  818. WEIL RS, Pappa K, Schade RN, Schrag AE, et al
    The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27176.
    PubMed    


  819. FORD KJ, Joop A, Memon RA, Wood KH, et al
    Pedestrian safety in patients with Parkinson's disease: A case-control study.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27124.
    PubMed     Abstract available


  820. STANDAERT DG
    What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.
    Mov Disord. 2017;32:1341-1342.
    PubMed    


    September 2017
  821. THEVATHASAN W, Debu B, Aziz T, Bloem BR, et al
    Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review.
    Mov Disord. 2017 Sep 28. doi: 10.1002/mds.27098.
    PubMed     Abstract available


  822. BIUNDO R, Weis L, Abbruzzese G, Calandra-Buonaura G, et al
    Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Mov Disord. 2017 Sep 27. doi: 10.1002/mds.27181.
    PubMed     Abstract available


  823. TESSITORE A, De Micco R, Giordano A, di Nardo F, et al
    Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27139.
    PubMed     Abstract available


  824. ROSE SJ, Harrast P, Donsante C, Fan X, et al
    Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27169.
    PubMed     Abstract available


  825. FULLARD ME, Xie SX, Marek K, Stern M, et al
    Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.
    Mov Disord. 2017 Sep 14. doi: 10.1002/mds.27127.
    PubMed     Abstract available


  826. SAME K, Ghazi Sherbaf F, Aarabi MH
    New link between Parkinson's and Alzheimer's: Research uncovers the role of mutant leucine rich repeat kinase 2 and amyloid precursor protein.
    Mov Disord. 2017 Sep 13. doi: 10.1002/mds.27170.
    PubMed    


  827. FRISALDI E, Carlino E, Zibetti M, Barbiani D, et al
    The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
    Mov Disord. 2017 Sep 12. doi: 10.1002/mds.27142.
    PubMed     Abstract available


  828. YANG F, Wolk A, Hakansson N, Pedersen NL, et al
    Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27120.
    PubMed     Abstract available


  829. HAN W, Sapkota S, Camicioli R, Dixon RA, et al
    Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27173.
    PubMed     Abstract available


  830. GHAHREMANI A, Chen R
    Deep brain stimulation modulates the shape of cortical beta oscillations in Parkinson's disease.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27144.
    PubMed    


  831. EUSEBI P, Giannandrea D, Biscetti L, Abraha I, et al
    Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27110.
    PubMed     Abstract available


  832. BRAKEDAL B, Flones I, Reiter SF, Torkildsen O, et al
    Glitazone use associated with reduced risk of Parkinson's disease.
    Mov Disord. 2017 Sep 1. doi: 10.1002/mds.27128.
    PubMed     Abstract available


  833. OBESO JA, Stamelou M, Goetz CG, Poewe W, et al
    Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.
    Mov Disord. 2017;32:1264-1310.
    PubMed     Abstract available



  834. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative
    Mov Disord. 2017;32:e1-e19.
    PubMed    


    August 2017
  835. TREZZI JP, Galozzi S, Jaeger C, Barkovits K, et al
    Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27132.
    PubMed     Abstract available


  836. HEINTZ-BUSCHART A, Pandey U, Wicke T, Sixel-Doring F, et al
    The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27105.
    PubMed     Abstract available


  837. TURCANO P, Mielke MM, Josephs KA, Bower JH, et al
    Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27125.
    PubMed     Abstract available


  838. PARNETTI L, Paciotti S, Eusebi P, Dardis A, et al
    Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27136.
    PubMed     Abstract available


  839. BORGHAMMER P
    How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27138.
    PubMed     Abstract available


  840. OERTEL W, Eggert K, Pahwa R, Tanner CM, et al
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Mov Disord. 2017 Aug 21. doi: 10.1002/mds.27131.
    PubMed     Abstract available


  841. CHAUDHURI KR, Jenner P
    Two hundred years since James Parkinson's essay on the shaking palsy-Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27104.
    PubMed    


  842. POLLARD EE
    Where we've gone "right" in the Parkinson's community.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27076.
    PubMed    


  843. ROCCA WA
    The future burden of Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27114.
    PubMed    


  844. MIYAUE N, Tada S, Ando R, Yabe H, et al
    cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27109.
    PubMed    


  845. BANDRES-CIGA S, Cookson MR
    Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder?
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27116.
    PubMed    


  846. GARCIA-SANZ P, Orgaz L, Bueno-Gil G, Espadas I, et al
    N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
    Mov Disord. 2017 Aug 5. doi: 10.1002/mds.27119.
    PubMed     Abstract available


  847. LILL CM, Klein C
    What would Dr. James Parkinson think today? The role of genetics in Parkinson's disease.
    Mov Disord. 2017;32:1115-1116.
    PubMed    


    July 2017
  848. CHUNG SJ, Shin JH, Cho KH, Lee Y, et al
    Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27106.
    PubMed     Abstract available


  849. DELPONT B, Lhommee E, Klinger H, Schmitt E, et al
    Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27101.
    PubMed     Abstract available


  850. OFORI E, Krismer F, Burciu RG, Pasternak O, et al
    Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Mov Disord. 2017 Jul 17. doi: 10.1002/mds.27100.
    PubMed     Abstract available


  851. THIBAULT L, Rascol O, Corvol JC, Ferreira J, et al
    New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
    Mov Disord. 2017 Jul 13. doi: 10.1002/mds.27055.
    PubMed    


  852. PAYAMI H
    The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27099.
    PubMed     Abstract available


  853. KOJOVIC M, Kassavetis P, Parees I, Georgiev D, et al
    Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27091.
    PubMed    


  854. CORREIA GUEDES L, Reimao S, Paulino P, Nunes RG, et al
    Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27083.
    PubMed    


  855. HEINZEL S, Bernhard FP, Roeben B, Nussbaum S, et al
    Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27062.
    PubMed    


  856. SAEZ-ATIENZAR S, Singleton AB
    Parkinson Disease and Clathrin Coat Dynamics at Synapses, Why Not?
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27097.
    PubMed    


  857. SONG N, Wang W, Jia F, Du X, et al
    Assessments of plasma ghrelin levels in the early stages of parkinson's disease.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27095.
    PubMed     Abstract available


  858. HUANG P, Tan YY, Liu DQ, Herzallah MM, et al
    Motor-symptom laterality affects acquisition in Parkinson's disease: A cognitive and functional magnetic resonance imaging study.
    Mov Disord. 2017;32:1047-1055.
    PubMed     Abstract available


  859. OBESO JA, Trenkwalder C
    What would Dr. James Parkinson think today? The 21st Annual Congress of the International Parkinson's disease and movement disorders society.
    Mov Disord. 2017;32:951-954.
    PubMed    


    June 2017
  860. ZABETIAN CP, Mata IF
    LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Mov Disord. 2017 Jun 28. doi: 10.1002/mds.27081.
    PubMed    


  861. GOETZ CG, Stebbins GT, Chung KA, Nicholas AP, et al
    Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
    Mov Disord. 2017 Jun 24. doi: 10.1002/mds.27092.
    PubMed    


  862. LHOMMEE E, Boyer F, Wack M, Pelissier P, et al
    Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation.
    Mov Disord. 2017 Jun 23. doi: 10.1002/mds.27065.
    PubMed     Abstract available


  863. STEINER LA, Neumann WJ, Staub-Bartelt F, Herz DM, et al
    Subthalamic beta dynamics mirror Parkinsonian bradykinesia months after neurostimulator implantation.
    Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27068.
    PubMed     Abstract available


  864. CHOTIBUT T, Meadows S, Kasanga EA, McInnis T, et al
    Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27077.
    PubMed     Abstract available


  865. BONET-PONCE L, Singleton AB
    Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27078.
    PubMed    


  866. CLAASSEN DO, Stark AJ, Spears CA, Petersen KJ, et al
    Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors.
    Mov Disord. 2017 Jun 19. doi: 10.1002/mds.27047.
    PubMed     Abstract available


  867. PELOSI A
    Cell-specific alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
    Mov Disord. 2017 Jun 16. doi: 10.1002/mds.27071.
    PubMed    


  868. FRIEDMAN JH
    Drug-induced parkinsonism.
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27050.
    PubMed    


  869. ROCCA WA, Savica R, Grossardt BR
    Response to Letter by Friedman on "Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study".
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27051.
    PubMed    


  870. HOOGLAND J, Boel JA, de Bie RMA, Geskus RB, et al
    Mild cognitive impairment as a risk factor for Parkinson's disease dementia.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27002.
    PubMed     Abstract available


  871. TITOVA N, Chaudhuri KR
    Personalized medicine in Parkinson's disease: Time to be precise.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27027.
    PubMed    


  872. LARSSON SC, Singleton AB, Nalls MA, Richards JB, et al
    No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study.
    Mov Disord. 2017 Jun 8. doi: 10.1002/mds.27069.
    PubMed     Abstract available


  873. ROSSI A, Berger K, Chen H, Leslie D, et al
    Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27063.
    PubMed     Abstract available


  874. KASSUBEK J, Huppertz HJ, Hoglinger GU
    Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27057.
    PubMed    


  875. KUMAR A
    Reprogramming the striatal stars: A new treatment option for Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27067.
    PubMed    


  876. QUATTRONE A, Nigro S
    MRI measures of brainstem in Parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27056.
    PubMed    


  877. MAHLKNECHT P, Akram H, Georgiev D, Tripoliti E, et al
    Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27042.
    PubMed     Abstract available


  878. PINA-FUENTES D, Little S, Oterdoom M, Neal S, et al
    Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.26959.
    PubMed    



  879. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2017;32 Suppl 2:S1-S1079.
    PubMed    


  880. MANDEMAKERS W, Quadri M, Stamelou M, Bonifati V, et al
    TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27061.
    PubMed     Abstract available


  881. PEREZ-SORIANO A, Arena JE, Dinelle K, Miao Q, et al
    PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27029.
    PubMed     Abstract available


  882. AKRAM H, Wu C, Hyam J, Foltynie T, et al
    l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease.
    Mov Disord. 2017;32:874-883.
    PubMed     Abstract available


  883. VAILLANCOURT DE
    What Would Dr. James Parkinson Think Today? Tau and Other Imaging Possibilities in Parkinson's Disease.
    Mov Disord. 2017;32:805-806.
    PubMed    


  884. LENKA A, Pal PK
    "Miro" in Parkinson's disease: Here, there, everywhere!
    Mov Disord. 2017;32:839.
    PubMed    


    May 2017
  885. NG ASL, Tan EK
    Linking statins and lipids in Parkinson's disease.
    Mov Disord. 2017 May 27. doi: 10.1002/mds.27053.
    PubMed    


  886. DELGADO-ALVARADO M, Gago B, Gorostidi A, Jimenez-Urbieta H, et al
    Tau/alpha-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27001.
    PubMed     Abstract available


  887. KIM YJ, Jeon J, Shin J, Kim NY, et al
    Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27019.
    PubMed     Abstract available


  888. COLLIER TJ, Kanaan NM, Kordower JH
    Aging and Parkinson's disease: Different sides of the same coin?
    Mov Disord. 2017 May 18. doi: 10.1002/mds.27037.
    PubMed     Abstract available


  889. PILOTTO A, Heinzel S, Suenkel U, Lerche S, et al
    Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.
    Mov Disord. 2017 May 16. doi: 10.1002/mds.27035.
    PubMed     Abstract available


  890. SHAHMOON S, Jahanshahi M
    Optimizing psychosocial adjustment after deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Mov Disord. 2017 May 15. doi: 10.1002/mds.27032.
    PubMed    


  891. YADAV AP, Nicolelis MAL
    Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.
    Mov Disord. 2017 May 12. doi: 10.1002/mds.27033.
    PubMed     Abstract available


  892. MEROLA A, Rosso M, Romagnolo A, Comi C, et al
    Peripheral neuropathy as marker of severe Parkinson's disease phenotype.
    Mov Disord. 2017 May 8. doi: 10.1002/mds.27025.
    PubMed    


  893. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force.
    Mov Disord. 2017;32:724-725.
    PubMed    


  894. POSTUMA RB
    Sleep Disorders and RBD: What Would James Parkinson Think?
    Mov Disord. 2017;32:705-707.
    PubMed    


  895. ST LOUIS EK, Boeve AR, Boeve BF
    REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
    Mov Disord. 2017;32:645-658.
    PubMed     Abstract available


  896. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings.
    Mov Disord. 2017;32:722-723.
    PubMed    


  897. MCKENNA D, Peever J
    Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder.
    Mov Disord. 2017;32:636-644.
    PubMed     Abstract available


  898. HOGL B, Stefani A
    Restless legs syndrome and periodic leg movements in patients with movement disorders: Specific considerations.
    Mov Disord. 2017;32:669-681.
    PubMed     Abstract available


    April 2017
  899. STROUWEN C, Molenaar EALM, Munks L, Keus SHJ, et al
    Training dual tasks together or apart in Parkinson's disease: Results from the DUALITY trial.
    Mov Disord. 2017 Apr 25. doi: 10.1002/mds.27014.
    PubMed     Abstract available


  900. DIEZ H, Cortes-Saladelafont E, Ormazabal A, Marmiese AF, et al
    Severe infantile parkinsonism because of a de novo mutation on DLP1 mitochondrial-peroxisomal protein.
    Mov Disord. 2017 Apr 24. doi: 10.1002/mds.27021.
    PubMed    


  901. OLSZEWSKA DA, Lynch T
    Nature's Parkin experiment: Nix-a novel protective mechanism in Parkinson's disease.
    Mov Disord. 2017 Apr 22. doi: 10.1002/mds.27015.
    PubMed    


  902. BEAULIEU ML, Muller MLTM, Bohnen NI
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26994.
    PubMed    


  903. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.27009.
    PubMed    


  904. FERESHTEHNEJAD SM, Montplaisir JY, Pelletier A, Gagnon JF, et al
    Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26989.
    PubMed     Abstract available


  905. BURTE F, Houghton D, Lowes H, Pyle A, et al
    metabolic profiling of Parkinson's disease and mild cognitive impairment.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26992.
    PubMed     Abstract available


  906. KOOLE M, Laere KV, Ahmad R, Ceccarini J, et al
    Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.27005.
    PubMed    


  907. CACACE F, Mineo D, Viscomi MT, Latagliata EC, et al
    Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26982.
    PubMed     Abstract available


  908. YANG X, An R, Xi J, Zheng J, et al
    Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26996.
    PubMed    


  909. OLANOW CW, Kieburtz K, Leinonen M, Elmer L, et al
    A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26941.
    PubMed     Abstract available


  910. LIU G, Sterling NW, Kong L, Lewis MM, et al
    Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.27006.
    PubMed     Abstract available


  911. KORDOWER JH
    What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Mov Disord. 2017;32:483-484.
    PubMed    


  912. BALCK A, Klein C
    Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection.
    Mov Disord. 2017;32:527.
    PubMed    


    March 2017
  913. ORGAZ L, Gil GB
    Modulating mitochondrial pyruvate carrier: A promising therapeutic target in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26962.
    PubMed    


  914. FOX SH, Metman LV, Nutt JG, Brodsky M, et al
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26976.
    PubMed     Abstract available


  915. PONT-SUNYER C, Tolosa E, Caspell-Garcia C, Coffey C, et al
    The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26964.
    PubMed     Abstract available


  916. LEHERICY S, Vaillancourt DE, Seppi K, Monchi O, et al
    The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26968.
    PubMed     Abstract available


  917. BARICHELLA M, Cereda E, Cassani E, Frazzitta G, et al
    A focus on Rome III criteria for the assessment of constipation in Parkinson's disease.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26974.
    PubMed    


  918. XU T, Wang S, Lalchandani RR, Ding JB, et al
    Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26938.
    PubMed     Abstract available


  919. MEROLA A, Romagnolo A, Comi C, Rosso M, et al
    Prevalence and burden of dysautonomia in advanced Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26970.
    PubMed    


  920. F HERNANDEZ L, Castela I, Ruiz-DeDiego I, Obeso JA, et al
    Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26947.
    PubMed     Abstract available


  921. ANDERKOVA L, Barton M, Rektorova I
    Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26956.
    PubMed     Abstract available


  922. PAGANO G, Niccolini F, Yousaf T, Wilson H, et al
    Urinary dysfunction in early de novo patients with Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26967.
    PubMed    


  923. PEREZ XA, Zhang D, Bordia T, Quik M, et al
    Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26955.
    PubMed     Abstract available


  924. HANSEN AK, Damholdt MF, Fedorova TD, Knudsen K, et al
    In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26961.
    PubMed     Abstract available


  925. GIANNOCCARO MP, La Morgia C, Rizzo G, Carelli V, et al
    Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.
    Mov Disord. 2017 Mar 2. doi: 10.1002/mds.26966.
    PubMed     Abstract available


  926. MARRAS C
    What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life.
    Mov Disord. 2017;32:364-365.
    PubMed    


    February 2017
  927. ESPAY AJ, Schwarzschild MA, Tanner CM, Fernandez HH, et al
    Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Mov Disord. 2017 Feb 24. doi: 10.1002/mds.26913.
    PubMed     Abstract available


  928. HORVATH K, Aschermann Z, Kovacs M, Makkos A, et al
    Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale.
    Mov Disord. 2017 Feb 20. doi: 10.1002/mds.26960.
    PubMed     Abstract available


  929. MIKI Y, Yoshizawa T, Morohashi S, Seino Y, et al
    Neuropathology of PARK14 is identical to idiopathic Parkinson's disease.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26952.
    PubMed    


  930. ROSA M, Arlotti M, Marceglia S, Cogiamanian F, et al
    Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26953.
    PubMed    


  931. HILL-BURNS EM, Debelius JW, Morton JT, Wissemann WT, et al
    Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Mov Disord. 2017 Feb 14. doi: 10.1002/mds.26942.
    PubMed     Abstract available


  932. PONZO V, Di Lorenzo F, Brusa L, Schirinzi T, et al
    Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26931.
    PubMed     Abstract available


  933. ANSARI M, Sobhani S
    Impaired glutamate release in GPe astrocytes, disinhibits striatopallidal transmission in Parkinsonian mice.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26943.
    PubMed    


  934. GALLEA C, Ewenczyk C, Degos B, Welter ML, et al
    Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders.
    Mov Disord. 2017 Feb 6. doi: 10.1002/mds.26923.
    PubMed     Abstract available


  935. DEL REY NL, Blesa J
    Parkinson's disease: Oh my gut!
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26933.
    PubMed    


  936. MAHLKNECHT P, Krismer F, Poewe W, Seppi K, et al
    Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26932.
    PubMed     Abstract available


  937. MOLLER L, Kassubek J, Sudmeyer M, Hilker R, et al
    Manual MRI morphometry in Parkinsonian syndromes.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26921.
    PubMed     Abstract available


  938. STRAFELLA AP, Bohnen NI, Perlmutter JS, Eidelberg D, et al
    Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26907.
    PubMed     Abstract available


  939. OLANOW CW, Kordower JH
    Targeting alpha-Synuclein as a therapy for Parkinson's disease: The battle begins.
    Mov Disord. 2017;32:203-207.
    PubMed    


  940. ALBIN RL
    What would Dr. James Parkinson think today? II. Neuroimaging in Parkinson's disease.
    Mov Disord. 2017;32:179-180.
    PubMed    


  941. EBRAHIMI R, Sobhani S, Abbastabar M
    Whether the dissociation between toxicity and alpha-synuclein inclusion will be a possible therapy for Parkinson's disease or not?
    Mov Disord. 2017;32:210.
    PubMed    



  942. Abstracts of the 1st Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2017;32 Suppl 1:S1-S90.
    PubMed    


    January 2017
  943. MORBERG BM, Malling AS, Jensen BR, Gredal O, et al
    Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26927.
    PubMed    


  944. VIDENOVIC A
    Management of sleep disorders in Parkinson's disease and multiple system atrophy.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26918.
    PubMed     Abstract available


  945. NOYCE AJ, R'Bibo L, Peress L, Bestwick JP, et al
    PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26898.
    PubMed     Abstract available


  946. QUADRI M, Breedveld GJ, Chang HC, Yeh TH, et al
    Mutations in TMEM230 are not a common cause of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26900.
    PubMed    


  947. MOHASEL S, Sobhani S
    The role of amyloidogenic proteins as a meeting point of type 2 diabetes and Parkinson's disease pathways.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26897.
    PubMed    


  948. VISANJI NP, Bhudhikanok GS, Mestre TA, Ghate T, et al
    Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26896.
    PubMed     Abstract available


  949. SCHNEIDER SA, Bras J
    Mouse models of kufor-rakeb disease link Parkinson's disease closer to neuronal ceroid lipofuscinosis, suggesting lysosomal dysfunction as shared mechanism.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26899.
    PubMed    


  950. BESTE C, Muckschel M, Rosales R, Domingo A, et al
    Striosomal dysfunction affects behavioral adaptation but not impulsivity-Evidence from X-linked dystonia-parkinsonism.
    Mov Disord. 2017 Jan 6. doi: 10.1002/mds.26895.
    PubMed     Abstract available


  951. SPATARO N, Roca-Umbert A, Cervera-Carles L, Valles M, et al
    Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients.
    Mov Disord. 2017;32:165-169.
    PubMed     Abstract available


  952. ZHANG M, Xi Z, Misquitta K, Sato C, et al
    C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism.
    Mov Disord. 2017;32:158-162.
    PubMed     Abstract available


  953. HARIZ M, Obeso JA
    What Would Dr. James Parkinson Think Today? I. The Role of Functional Neurosurgery for Parkinson's Disease.
    Mov Disord. 2017;32:2-4.
    PubMed    


  954. BLUMENFELD Z, Koop MM, Prieto TE, Shreve LA, et al
    Sixty-hertz stimulation improves bradykinesia and amplifies subthalamic low-frequency oscillations.
    Mov Disord. 2017;32:80-88.
    PubMed     Abstract available


  955. CHO H, Choi JY, Hwang MS, Lee SH, et al
    Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy.
    Mov Disord. 2017;32:134-140.
    PubMed     Abstract available


  956. VALSKY D, Marmor-Levin O, Deffains M, Eitan R, et al
    Stop! border ahead: Automatic detection of subthalamic exit during deep brain stimulation surgery.
    Mov Disord. 2017;32:70-79.
    PubMed     Abstract available


    December 2016
  957. LANGLEY J, Huddleston DE, Sedlacik J, Boelmans K, et al
    Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26883.
    PubMed     Abstract available


  958. RAHMANI F, Kamalian A, Aarabi MH
    New evidence comes to light: How is alpha-synuclein aggregation related to mitochondrial protein import in Parkinson's disease?
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26889.
    PubMed    


  959. BLAUWENDRAAT C, Nalls MA, Federoff M, Pletnikova O, et al
    ADORA1 mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26886.
    PubMed    


  960. SENEK M, Nielsen EI, Nyholm D
    Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26855.
    PubMed     Abstract available


  961. PAL GD, Ouyang B, Serrano G, Shill HA, et al
    Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26882.
    PubMed     Abstract available


  962. DZAMKO N, Gysbers AM, Bandopadhyay R, Bolliger MF, et al
    LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26892.
    PubMed     Abstract available


  963. MARTINEZ-MARTIN P
    What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26885.
    PubMed     Abstract available


  964. GOETZ CG, Liu Y, Stebbins GT, Wang L, et al
    Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Mov Disord. 2016;31:1865-1873.
    PubMed     Abstract available


  965. WILLIS AW, Thibault DP, Schmidt PN, Dorsey ER, et al
    Hospital care for mental health and substance abuse conditions in Parkinson's disease.
    Mov Disord. 2016;31:1810-1819.
    PubMed     Abstract available


  966. SHI CH, Zhang SY, Yang ZH, Yang J, et al
    A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.
    Mov Disord. 2016;31:1905-1909.
    PubMed     Abstract available


    November 2016
  967. DE PABLO-FERNANDEZ E, Courtney R, Holton JL, Warner TT, et al
    Hypothalamic alpha-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease.
    Mov Disord. 2016 Nov 28. doi: 10.1002/mds.26868.
    PubMed    


  968. KNUDSEN K, Krogh K, Ostergaard K, Borghammer P, et al
    Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26866.
    PubMed     Abstract available


  969. PILLAS M, Selai C, Schrag A
    Rasch analysis of the carers quality of life questionnaire for parkinsonism.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26877.
    PubMed     Abstract available


  970. RAUSCHENDORF MA, Jost M, Stock F, Zimmer A, et al
    Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26876.
    PubMed    


  971. HE YC, Huang P, Li QQ, Sun Q, et al
    TMEM230 stop codon mutation is rare in parkinson's disease and essential tremor in eastern China.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26875.
    PubMed    


  972. POLITIS M, Sauerbier A, Loane C, Pavese N, et al
    Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
    Mov Disord. 2016 Nov 17. doi: 10.1002/mds.26848.
    PubMed     Abstract available


  973. GALIMBERTI D, Cioffi SM, Fenoglio C, Serpente M, et al
    Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26872.
    PubMed    


  974. FIFEL K
    Alterations of the circadian system in Parkinson's disease patients.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26865.
    PubMed     Abstract available


  975. ISOTALO J, Vahlberg T, Kaasinen V
    Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26862.
    PubMed    


  976. XIE T, Kang UJ
    Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26861.
    PubMed    


  977. GAARE JJ, Skeie GO, Tzoulis C, Larsen JP, et al
    Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26856.
    PubMed     Abstract available


  978. PINTO DE SOUZA C, Hamani C, Oliveira Souza C, Lopez Contreras WO, et al
    Spinal cord stimulation improves gait in patients with Parkinson's disease previously treated with deep brain stimulation.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26850.
    PubMed     Abstract available


  979. KLETTNER A, Tholey A, Wiegandt A, Richert E, et al
    Reduction of GAPDH in lenses of Parkinson's disease patients: A possible new biomarker.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26863.
    PubMed     Abstract available


  980. BEUDEL M, Oswal A, Jha A, Foltynie T, et al
    Oscillatory Beta Power Correlates With Akinesia-Rigidity in the Parkinsonian Subthalamic Nucleus.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26860.
    PubMed    


  981. DI BIASE L, Fasano A
    Reply to: Comments on recent viewpoint article by Lazzaro di Biase and Alfonso Fasano titled "Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?"
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26859.
    PubMed    


  982. NEUMANN WJ, Kuhn AA
    Subthalamic beta power-Unified Parkinson's disease rating scale III correlations require akinetic symptoms.
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26858.
    PubMed    


  983. SGAMBATO-FAURE V
    Control of the direct pathway by cholinergic interneurons is involved in parkinsonian motor symptoms.
    Mov Disord. 2016 Nov 2. doi: 10.1002/mds.26840.
    PubMed    


    October 2016
  984. FOO JN, Lee J, Tan LC, Liu J, et al
    Large 3-Mb deletions at 22q11.2 locus in parkinson's disease and schizophrenia.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26822.
    PubMed    


  985. HUGHES KC, Gao X, Kim IY, Rimm EB, et al
    Intake of antioxidant vitamins and risk of parkinson's disease.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26819.
    PubMed     Abstract available


  986. TINAZZI M, Geroin C, Gandolfi M, Smania N, et al
    Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26829.
    PubMed     Abstract available


  987. MANGESIUS S, Krismer F, Gizewski ER, Muller C, et al
    1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26823.
    PubMed    


  988. SAVICA R, Grossardt BR, Bower JH, Ahlskog JE, et al
    Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26839.
    PubMed     Abstract available


  989. TARSY D
    Addition of a virtual reality component to treadmill training to reduce fall risk in older adults, including individuals with Parkinson's disease.
    Mov Disord. 2016 Oct 19. doi: 10.1002/mds.26843.
    PubMed    


  990. KHODADADI H, Azcona LJ, Aghamollaii V, Omrani MD, et al
    PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26824.
    PubMed     Abstract available


  991. TROSTER AI, Jankovic J, Tagliati M, Peichel D, et al
    Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26827.
    PubMed     Abstract available


  992. PYLE A, Lowes H, Brennan R, Kurzawa-Akanbi M, et al
    Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26825.
    PubMed    


  993. BALINT B, Bhatia KP
    SLC39A14 mutations expand the spectrum of manganese transporter defects causing parkinsonism-dystonia.
    Mov Disord. 2016 Oct 14. doi: 10.1002/mds.26821.
    PubMed    


  994. KLEIN C, Lochte T, Delamonte SM, Braenne I, et al
    PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical Features and Neuropathology.
    Mov Disord. 2016 Oct 6. doi: 10.1002/mds.26814.
    PubMed    


  995. POLLI A, Weis L, Biundo R, Thacker M, et al
    Anatomical and functional correlates of persistent pain in parkinson's disease.
    Mov Disord. 2016 Oct 5. doi: 10.1002/mds.26826.
    PubMed     Abstract available


    September 2016
  996. PONS R, Kekou K, Antonellou R, Svingou M, et al
    Analysis of a founder mutation in the TH gene in a cohort of greek patients with Parkinson's disease.
    Mov Disord. 2016 Sep 26. doi: 10.1002/mds.26807.
    PubMed    


  997. SVENSSON E, Horvath-Puho E, Stokholm MG, Sorensen HT, et al
    Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26761.
    PubMed     Abstract available


  998. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naive cohort.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26742.
    PubMed     Abstract available


  999. WONG YC, Krainc D
    Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26802.
    PubMed     Abstract available


  1000. KETT LR, Dauer WT
    Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26797.
    PubMed     Abstract available


  1001. RIEDEL O
    Bringing light into the darkness: Dependence in Parkinson's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26795.
    PubMed    


  1002. DELVAL A, Rambour M, Tard C, Dujardin K, et al
    Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26762.
    PubMed     Abstract available


    April 2016
  1003. WEISS D, Herrmann S, Wang L, Schulte C, et al
    Alpha-synuclein gene variants may predict neurostimulation outcome.
    Mov Disord. 2016;31:601-3.
    PubMed    


  1004. LAWTON M, Kasten M, May MT, Mollenhauer B, et al
    Validation of conversion between mini-mental state examination and montreal cognitive assessment.
    Mov Disord. 2016;31:593-6.
    PubMed     Abstract available


  1005. LANG AE, Rodriguez RL, Boyd JT, Chouinard S, et al
    Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Mov Disord. 2016;31:538-46.
    PubMed     Abstract available


    March 2016
  1006. MESTRE TA, Lang AE, Okun MS
    Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mov Disord. 2016;31:290-6.
    PubMed     Abstract available


  1007. OROPESA-RUIZ JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, et al
    Low serum uric acid levels in progressive supranuclear palsy.
    Mov Disord. 2016;31:402-5.
    PubMed     Abstract available


  1008. WILE DJ, Dinelle K, Vafai N, McKenzie J, et al
    A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
    Mov Disord. 2016;31:405-9.
    PubMed     Abstract available


  1009. WALTER U, Muller JU, Rosche J, Kirsch M, et al
    Magnetic resonance-transcranial ultrasound fusion imaging: A novel tool for brain electrode location.
    Mov Disord. 2016;31:302-9.
    PubMed     Abstract available


    February 2016
  1010. STEFANOVA N, Kordower JH, Wenning GK
    Preface.
    Mov Disord. 2016;31:151.
    PubMed    


  1011. RICCIARDI L, Petrucci S, Di Giuda D, Serra L, et al
    The Contursi Family 20 Years Later: Intrafamilial Phenotypic Variability of the SNCA p.A53T Mutation.
    Mov Disord. 2016;31:257-8.
    PubMed    


  1012. RUFFMANN C, Parkkinen L
    Gut Feelings About alpha-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?
    Mov Disord. 2016;31:193-202.
    PubMed     Abstract available


  1013. CALO L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M, et al
    Synaptic failure and alpha-synuclein.
    Mov Disord. 2016;31:169-77.
    PubMed     Abstract available


  1014. BERGSTROM AL, Kallunki P, Fog K
    Development of Passive Immunotherapies for Synucleinopathies.
    Mov Disord. 2016;31:203-13.
    PubMed     Abstract available


  1015. VALERA E, Masliah E
    Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Mov Disord. 2016;31:225-34.
    PubMed     Abstract available


  1016. MCCANN H, Cartwright H, Halliday GM
    Neuropathology of alpha-synuclein propagation and braak hypothesis.
    Mov Disord. 2016;31:152-60.
    PubMed     Abstract available


  1017. SCHNEEBERGER A, Tierney L, Mandler M
    Active immunization therapies for Parkinson's disease and multiple system atrophy.
    Mov Disord. 2016;31:214-24.
    PubMed     Abstract available


    January 2016
  1018. CARTA M, Cenci MA
    On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Mov Disord. 2016;31:149.
    PubMed    


  1019. OLANOW CW, Poewe W
    Eldad Melamed 1942-2015: Ave atque--A memorial.
    Mov Disord. 2016;31:39-40.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: